SK99097A3 - Cells for the production of recombinant adenoviruses - Google Patents

Cells for the production of recombinant adenoviruses Download PDF

Info

Publication number: SK99097A3
Authority: SK; Slovakia
Prior art keywords: region; adenovirus; plasmid; cell; orf6
Prior art date: 1995-01-20

Application number

SK990-97A

Other languages

English (en)

Slovak (sk)

Inventor

Jean-Francois Dedieu

Martine Latta

Cecile Orsini

Michel Perricaudet

Emmanuelle Vigne

Patrice Yeh

Edouard Prost

Original Assignee

Rhone Poulenc Rorer Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-01-20

Filing date

1996-01-19

Publication date

1998-02-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27253011&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK99097(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-01-20 Priority claimed from FR9500747A external-priority patent/FR2729674B1/fr

1995-06-01 Priority claimed from FR9506532A external-priority patent/FR2741891B1/fr

1995-09-08 Priority claimed from FR9510541A external-priority patent/FR2738575B1/fr

1996-01-19 Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa

1998-02-04 Publication of SK99097A3 publication Critical patent/SK99097A3/sk

Links

241000701161 unidentified adenovirus Species 0.000 title claims abstract description 163
238000004519 manufacturing process Methods 0.000 title claims abstract description 43
101710087110 ORF6 protein Proteins 0.000 claims abstract description 85
101710095001 Uncharacterized protein in nifU 5'region Proteins 0.000 claims abstract description 84
230000002950 deficient Effects 0.000 claims abstract description 59
239000013612 plasmid Substances 0.000 claims description 179
239000012634 fragment Substances 0.000 claims description 98
241000700605 Viruses Species 0.000 claims description 88
230000037430 deletion Effects 0.000 claims description 83
238000012217 deletion Methods 0.000 claims description 83
108090000623 proteins and genes Proteins 0.000 claims description 81
239000002773 nucleotide Substances 0.000 claims description 52
125000003729 nucleotide group Chemical group 0.000 claims description 52
238000000034 method Methods 0.000 claims description 51
241000702421 Dependoparvovirus Species 0.000 claims description 35
101710110895 Uncharacterized 7.3 kDa protein in cox-rep intergenic region Proteins 0.000 claims description 31
208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 claims description 23
102000003676 Glucocorticoid Receptors Human genes 0.000 claims description 21
108090000079 Glucocorticoid Receptors Proteins 0.000 claims description 21
230000006870 function Effects 0.000 claims description 21
230000001939 inductive effect Effects 0.000 claims description 20
241000713333 Mouse mammary tumor virus Species 0.000 claims description 18
238000004113 cell culture Methods 0.000 claims description 17
102100031725 Cortactin-binding protein 2 Human genes 0.000 claims description 16
241000282414 Homo sapiens Species 0.000 claims description 16
101710197985 Probable protein Rev Proteins 0.000 claims description 16
101000833492 Homo sapiens Jouberin Proteins 0.000 claims description 13
101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 claims description 13
102100024407 Jouberin Human genes 0.000 claims description 13
150000007523 nucleic acids Chemical class 0.000 claims description 13
241000598171 Human adenovirus sp. Species 0.000 claims description 11
102000039446 nucleic acids Human genes 0.000 claims description 10
108020004707 nucleic acids Proteins 0.000 claims description 10
101000768957 Acholeplasma phage L2 Uncharacterized 37.2 kDa protein Proteins 0.000 claims description 9
101000823746 Acidianus ambivalens Uncharacterized 17.7 kDa protein in bps2 3'region Proteins 0.000 claims description 9
101000916369 Acidianus ambivalens Uncharacterized protein in sor 5'region Proteins 0.000 claims description 9
101000769342 Acinetobacter guillouiae Uncharacterized protein in rpoN-murA intergenic region Proteins 0.000 claims description 9
101000823696 Actinobacillus pleuropneumoniae Uncharacterized glycosyltransferase in aroQ 3'region Proteins 0.000 claims description 9
101000786513 Agrobacterium tumefaciens (strain 15955) Uncharacterized protein outside the virF region Proteins 0.000 claims description 9
101000618005 Alkalihalobacillus pseudofirmus (strain ATCC BAA-2126 / JCM 17055 / OF4) Uncharacterized protein BpOF4_00885 Proteins 0.000 claims description 9
102100020724 Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Human genes 0.000 claims description 9
101000967489 Azorhizobium caulinodans (strain ATCC 43989 / DSM 5975 / JCM 20966 / LMG 6465 / NBRC 14845 / NCIMB 13405 / ORS 571) Uncharacterized protein AZC_3924 Proteins 0.000 claims description 9
101000823761 Bacillus licheniformis Uncharacterized 9.4 kDa protein in flaL 3'region Proteins 0.000 claims description 9
101000819719 Bacillus methanolicus Uncharacterized N-acetyltransferase in lysA 3'region Proteins 0.000 claims description 9
101000789586 Bacillus subtilis (strain 168) UPF0702 transmembrane protein YkjA Proteins 0.000 claims description 9
101000792624 Bacillus subtilis (strain 168) Uncharacterized protein YbxH Proteins 0.000 claims description 9
101000790792 Bacillus subtilis (strain 168) Uncharacterized protein YckC Proteins 0.000 claims description 9
101000819705 Bacillus subtilis (strain 168) Uncharacterized protein YlxR Proteins 0.000 claims description 9
101000948218 Bacillus subtilis (strain 168) Uncharacterized protein YtxJ Proteins 0.000 claims description 9
101000718627 Bacillus thuringiensis subsp. kurstaki Putative RNA polymerase sigma-G factor Proteins 0.000 claims description 9
101000641200 Bombyx mori densovirus Putative non-structural protein Proteins 0.000 claims description 9
241000701157 Canine mastadenovirus A Species 0.000 claims description 9
101000947633 Claviceps purpurea Uncharacterized 13.8 kDa protein Proteins 0.000 claims description 9
101000948901 Enterobacteria phage T4 Uncharacterized 16.0 kDa protein in segB-ipI intergenic region Proteins 0.000 claims description 9
101000805958 Equine herpesvirus 4 (strain 1942) Virion protein US10 homolog Proteins 0.000 claims description 9
101000790442 Escherichia coli Insertion element IS2 uncharacterized 11.1 kDa protein Proteins 0.000 claims description 9
101000788354 Escherichia phage P2 Uncharacterized 8.2 kDa protein in gpA 5'region Proteins 0.000 claims description 9
101000770304 Frankia alni UPF0460 protein in nifX-nifW intergenic region Proteins 0.000 claims description 9
101000797344 Geobacillus stearothermophilus Putative tRNA (cytidine(34)-2'-O)-methyltransferase Proteins 0.000 claims description 9
101000748410 Geobacillus stearothermophilus Uncharacterized protein in fumA 3'region Proteins 0.000 claims description 9
101000772675 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) UPF0438 protein HI_0847 Proteins 0.000 claims description 9
101000631019 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Uncharacterized protein HI_0350 Proteins 0.000 claims description 9
101000768938 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 8.9 kDa protein in int-C1 intergenic region Proteins 0.000 claims description 9
101000785414 Homo sapiens Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Proteins 0.000 claims description 9
101000782488 Junonia coenia densovirus (isolate pBRJ/1990) Putative non-structural protein NS2 Proteins 0.000 claims description 9
101000811523 Klebsiella pneumoniae Uncharacterized 55.8 kDa protein in cps region Proteins 0.000 claims description 9
101000818409 Lactococcus lactis subsp. lactis Uncharacterized HTH-type transcriptional regulator in lacX 3'region Proteins 0.000 claims description 9
101000878851 Leptolyngbya boryana Putative Fe(2+) transport protein A Proteins 0.000 claims description 9
101000758828 Methanosarcina barkeri (strain Fusaro / DSM 804) Uncharacterized protein Mbar_A1602 Proteins 0.000 claims description 9
101001122401 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF3 Proteins 0.000 claims description 9
101001055788 Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) Pentapeptide repeat protein MfpA Proteins 0.000 claims description 9
101000740670 Orgyia pseudotsugata multicapsid polyhedrosis virus Protein C42 Proteins 0.000 claims description 9
101000769182 Photorhabdus luminescens Uncharacterized protein in pnp 3'region Proteins 0.000 claims description 9
101000961392 Pseudescherichia vulneris Uncharacterized 29.9 kDa protein in crtE 3'region Proteins 0.000 claims description 9
101000731030 Pseudomonas oleovorans Poly(3-hydroxyalkanoate) polymerase 2 Proteins 0.000 claims description 9
101001065485 Pseudomonas putida Probable fatty acid methyltransferase Proteins 0.000 claims description 9
101000711023 Rhizobium leguminosarum bv. trifolii Uncharacterized protein in tfuA 3'region Proteins 0.000 claims description 9
101000948156 Rhodococcus erythropolis Uncharacterized 47.3 kDa protein in thcA 5'region Proteins 0.000 claims description 9
101000917565 Rhodococcus fascians Uncharacterized 33.6 kDa protein in fasciation locus Proteins 0.000 claims description 9
101000790284 Saimiriine herpesvirus 2 (strain 488) Uncharacterized 9.5 kDa protein in DHFR 3'region Proteins 0.000 claims description 9
101000936719 Streptococcus gordonii Accessory Sec system protein Asp3 Proteins 0.000 claims description 9
101000788499 Streptomyces coelicolor Uncharacterized oxidoreductase in mprA 5'region Proteins 0.000 claims description 9
101001102841 Streptomyces griseus Purine nucleoside phosphorylase ORF3 Proteins 0.000 claims description 9
101000708557 Streptomyces lincolnensis Uncharacterized 17.2 kDa protein in melC2-rnhH intergenic region Proteins 0.000 claims description 9
101000649826 Thermotoga neapolitana Putative anti-sigma factor antagonist TM1081 homolog Proteins 0.000 claims description 9
101000827562 Vibrio alginolyticus Uncharacterized protein in proC 3'region Proteins 0.000 claims description 9
101000778915 Vibrio parahaemolyticus serotype O3:K6 (strain RIMD 2210633) Uncharacterized membrane protein VP2115 Proteins 0.000 claims description 9
239000003862 glucocorticoid Substances 0.000 claims description 9
-1 cationic lipid Chemical class 0.000 claims description 7
229940088597 hormone Drugs 0.000 claims description 7
239000005556 hormone Substances 0.000 claims description 7
238000013519 translation Methods 0.000 claims description 7
230000027455 binding Effects 0.000 claims description 6
108700039691 Genetic Promoter Regions Proteins 0.000 claims description 5
108020005497 Nuclear hormone receptor Proteins 0.000 claims description 5
102000006255 nuclear receptors Human genes 0.000 claims description 5
108020004017 nuclear receptors Proteins 0.000 claims description 5
229940037128 systemic glucocorticoids Drugs 0.000 claims description 5
102100038909 Caveolin-2 Human genes 0.000 claims description 4
101000740981 Homo sapiens Caveolin-2 Proteins 0.000 claims description 4
102100021244 Integral membrane protein GPR180 Human genes 0.000 claims description 4
101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 claims description 4
101710130262 Probable Vpr-like protein Proteins 0.000 claims description 4
239000003795 chemical substances by application Substances 0.000 claims description 4
239000003446 ligand Substances 0.000 claims description 4
210000004027 cell Anatomy 0.000 description 198
241001135569 Human adenovirus 5 Species 0.000 description 37
230000014509 gene expression Effects 0.000 description 34
230000003612 virological effect Effects 0.000 description 32
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 28
208000015181 infectious disease Diseases 0.000 description 24
108020004414 DNA Proteins 0.000 description 22
238000010276 construction Methods 0.000 description 22
239000013598 vector Substances 0.000 description 18
239000000463 material Substances 0.000 description 15
102000004169 proteins and genes Human genes 0.000 description 15
230000001225 therapeutic effect Effects 0.000 description 15
238000004458 analytical method Methods 0.000 description 14
229960003957 dexamethasone Drugs 0.000 description 14
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 14
238000010367 cloning Methods 0.000 description 13
230000010076 replication Effects 0.000 description 12
230000002458 infectious effect Effects 0.000 description 11
239000002245 particle Substances 0.000 description 11
238000001890 transfection Methods 0.000 description 11
230000001105 regulatory effect Effects 0.000 description 10
230000003321 amplification Effects 0.000 description 9
230000000694 effects Effects 0.000 description 9
238000003199 nucleic acid amplification method Methods 0.000 description 9
230000029087 digestion Effects 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
239000000523 sample Substances 0.000 description 8
108700026244 Open Reading Frames Proteins 0.000 description 7
230000008901 benefit Effects 0.000 description 7
238000012546 transfer Methods 0.000 description 7
241000588724 Escherichia coli Species 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
238000002105 Southern blotting Methods 0.000 description 6
108700005077 Viral Genes Proteins 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
239000000203 mixture Substances 0.000 description 6
238000003757 reverse transcription PCR Methods 0.000 description 6
238000013518 transcription Methods 0.000 description 6
230000035897 transcription Effects 0.000 description 6
230000029812 viral genome replication Effects 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
108010076504 Protein Sorting Signals Proteins 0.000 description 5
239000000835 fiber Substances 0.000 description 5
238000001415 gene therapy Methods 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
239000007788 liquid Substances 0.000 description 5
230000036961 partial effect Effects 0.000 description 5
230000008488 polyadenylation Effects 0.000 description 5
230000003362 replicative effect Effects 0.000 description 5
239000000243 solution Substances 0.000 description 5
241000282465 Canis Species 0.000 description 4
108010017826 DNA Polymerase I Proteins 0.000 description 4
102000004594 DNA Polymerase I Human genes 0.000 description 4
241000701533 Escherichia virus T4 Species 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
108091028043 Nucleic acid sequence Proteins 0.000 description 4
239000011543 agarose gel Substances 0.000 description 4
230000000692 anti-sense effect Effects 0.000 description 4
108010005774 beta-Galactosidase Proteins 0.000 description 4
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 4
108091092328 cellular RNA Proteins 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
238000012761 co-transfection Methods 0.000 description 4
238000011109 contamination Methods 0.000 description 4
230000000120 cytopathologic effect Effects 0.000 description 4
230000004927 fusion Effects 0.000 description 4
108020001507 fusion proteins Proteins 0.000 description 4
102000037865 fusion proteins Human genes 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
230000028993 immune response Effects 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
238000003780 insertion Methods 0.000 description 4
230000037431 insertion Effects 0.000 description 4
230000008520 organization Effects 0.000 description 4
230000001575 pathological effect Effects 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
238000000746 purification Methods 0.000 description 4
108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
229920000936 Agarose Polymers 0.000 description 3
201000009030 Carcinoma Diseases 0.000 description 3
108091026890 Coding region Proteins 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
102000053602 DNA Human genes 0.000 description 3
241000282412 Homo Species 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
238000012408 PCR amplification Methods 0.000 description 3
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 3
210000004899 c-terminal region Anatomy 0.000 description 3
239000001506 calcium phosphate Substances 0.000 description 3
229910000389 calcium phosphate Inorganic materials 0.000 description 3
235000011010 calcium phosphates Nutrition 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
239000000284 extract Substances 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
238000002744 homologous recombination Methods 0.000 description 3
230000006801 homologous recombination Effects 0.000 description 3
239000003550 marker Substances 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
230000005855 radiation Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000002103 transcriptional effect Effects 0.000 description 3
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
230000009385 viral infection Effects 0.000 description 3
108010027345 wheylin-1 peptide Proteins 0.000 description 3
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
108010085238 Actins Proteins 0.000 description 2
102000007469 Actins Human genes 0.000 description 2
108010056962 Adenovirus E4 Proteins Proteins 0.000 description 2
108700026758 Adenovirus hexon capsid Proteins 0.000 description 2
KSUALAGYYLQSHJ-RCWTZXSCSA-N Arg-Met-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KSUALAGYYLQSHJ-RCWTZXSCSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
208000003322 Coinfection Diseases 0.000 description 2
102000012410 DNA Ligases Human genes 0.000 description 2
108010061982 DNA Ligases Proteins 0.000 description 2
230000004543 DNA replication Effects 0.000 description 2
102000052510 DNA-Binding Proteins Human genes 0.000 description 2
101710096438 DNA-binding protein Proteins 0.000 description 2
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
HGCNKOLVKRAVHD-UHFFFAOYSA-N L-Met-L-Phe Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-UHFFFAOYSA-N 0.000 description 2
UGTZHPSKYRIGRJ-YUMQZZPRSA-N Lys-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O UGTZHPSKYRIGRJ-YUMQZZPRSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
YLBUMXYVQCHBPR-ULQDDVLXSA-N Met-Leu-Tyr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YLBUMXYVQCHBPR-ULQDDVLXSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
238000000636 Northern blotting Methods 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 description 2
108020005202 Viral DNA Proteins 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
230000009471 action Effects 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
210000000805 cytoplasm Anatomy 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
230000001086 cytosolic effect Effects 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
238000012239 gene modification Methods 0.000 description 2
230000005017 genetic modification Effects 0.000 description 2
235000013617 genetically modified food Nutrition 0.000 description 2
239000000017 hydrogel Substances 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
108010009298 lysylglutamic acid Proteins 0.000 description 2
239000002609 medium Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
108010068488 methionylphenylalanine Proteins 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000035772 mutation Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
230000001902 propagating effect Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
230000009291 secondary effect Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000001131 transforming effect Effects 0.000 description 2
230000014621 translational initiation Effects 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
108010057856 Adenovirus E2 Proteins Proteins 0.000 description 1
ZIWWTZWAKYBUOB-CIUDSAMLSA-N Ala-Asp-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O ZIWWTZWAKYBUOB-CIUDSAMLSA-N 0.000 description 1
WKOBSJOZRJJVRZ-FXQIFTODSA-N Ala-Glu-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WKOBSJOZRJJVRZ-FXQIFTODSA-N 0.000 description 1
XYTNPQNAZREREP-XQXXSGGOSA-N Ala-Glu-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XYTNPQNAZREREP-XQXXSGGOSA-N 0.000 description 1
MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 1
AWNAEZICPNGAJK-FXQIFTODSA-N Ala-Met-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O AWNAEZICPNGAJK-FXQIFTODSA-N 0.000 description 1
108010011667 Ala-Phe-Ala Proteins 0.000 description 1
VNFSAYFQLXPHPY-CIQUZCHMSA-N Ala-Thr-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VNFSAYFQLXPHPY-CIQUZCHMSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
102000007592 Apolipoproteins Human genes 0.000 description 1
108010071619 Apolipoproteins Proteins 0.000 description 1
102000013918 Apolipoproteins E Human genes 0.000 description 1
108010025628 Apolipoproteins E Proteins 0.000 description 1
XEPSCVXTCUUHDT-AVGNSLFASA-N Arg-Arg-Leu Natural products CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCCN=C(N)N XEPSCVXTCUUHDT-AVGNSLFASA-N 0.000 description 1
AHPWQERCDZTTNB-FXQIFTODSA-N Arg-Cys-Cys Chemical compound C(C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)O)N)CN=C(N)N AHPWQERCDZTTNB-FXQIFTODSA-N 0.000 description 1
FFEUXEAKYRCACT-PEDHHIEDSA-N Arg-Ile-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(O)=O FFEUXEAKYRCACT-PEDHHIEDSA-N 0.000 description 1
NOZYDJOPOGKUSR-AVGNSLFASA-N Arg-Leu-Met Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O NOZYDJOPOGKUSR-AVGNSLFASA-N 0.000 description 1
NMRHDSAOIURTNT-RWMBFGLXSA-N Arg-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N NMRHDSAOIURTNT-RWMBFGLXSA-N 0.000 description 1
OGSQONVYSTZIJB-WDSOQIARSA-N Arg-Leu-Trp Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)CCCN=C(N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O OGSQONVYSTZIJB-WDSOQIARSA-N 0.000 description 1
NIELFHOLFTUZME-HJWJTTGWSA-N Arg-Phe-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O NIELFHOLFTUZME-HJWJTTGWSA-N 0.000 description 1
UIUXXFIKWQVMEX-UFYCRDLUSA-N Arg-Phe-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O UIUXXFIKWQVMEX-UFYCRDLUSA-N 0.000 description 1
AIFHRTPABBBHKU-RCWTZXSCSA-N Arg-Thr-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O AIFHRTPABBBHKU-RCWTZXSCSA-N 0.000 description 1
VILLWIDTHYPSLC-PEFMBERDSA-N Asp-Glu-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VILLWIDTHYPSLC-PEFMBERDSA-N 0.000 description 1
DTNUIAJCPRMNBT-WHFBIAKZSA-N Asp-Gly-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(O)=O DTNUIAJCPRMNBT-WHFBIAKZSA-N 0.000 description 1
MGSVBZIBCCKGCY-ZLUOBGJFSA-N Asp-Ser-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MGSVBZIBCCKGCY-ZLUOBGJFSA-N 0.000 description 1
YIDFBWRHIYOYAA-LKXGYXEUSA-N Asp-Ser-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O YIDFBWRHIYOYAA-LKXGYXEUSA-N 0.000 description 1
108010077805 Bacterial Proteins Proteins 0.000 description 1
102100021277 Beta-secretase 2 Human genes 0.000 description 1
101710150190 Beta-secretase 2 Proteins 0.000 description 1
108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
101100328086 Caenorhabditis elegans cla-1 gene Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
101150044789 Cap gene Proteins 0.000 description 1
108090000565 Capsid Proteins Proteins 0.000 description 1
102100023321 Ceruloplasmin Human genes 0.000 description 1
108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
108020004394 Complementary RNA Proteins 0.000 description 1
LYSHSHHDBVKJRN-JBDRJPRFSA-N Cys-Ile-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CS)N LYSHSHHDBVKJRN-JBDRJPRFSA-N 0.000 description 1
DYBIDOHFRRUMLW-CIUDSAMLSA-N Cys-Leu-Cys Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)CS)C(=O)N[C@@H](CS)C(O)=O DYBIDOHFRRUMLW-CIUDSAMLSA-N 0.000 description 1
VOBMMKMWSIVIOA-SRVKXCTJSA-N Cys-Lys-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N VOBMMKMWSIVIOA-SRVKXCTJSA-N 0.000 description 1
ORYFTECKJZTNQP-DCAQKATOSA-N Cys-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CS)N ORYFTECKJZTNQP-DCAQKATOSA-N 0.000 description 1
CYHMMWIOEUVHHZ-IHRRRGAJSA-N Cys-Met-Tyr Chemical compound SC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CYHMMWIOEUVHHZ-IHRRRGAJSA-N 0.000 description 1
YXQDRIRSAHTJKM-IMJSIDKUSA-N Cys-Ser Chemical compound SC[C@H](N)C(=O)N[C@@H](CO)C(O)=O YXQDRIRSAHTJKM-IMJSIDKUSA-N 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
238000007400 DNA extraction Methods 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
101100016370 Danio rerio hsp90a.1 gene Proteins 0.000 description 1
102100036912 Desmin Human genes 0.000 description 1
108010044052 Desmin Proteins 0.000 description 1
101100285708 Dictyostelium discoideum hspD gene Proteins 0.000 description 1
208000032928 Dyslipidaemia Diseases 0.000 description 1
108010069091 Dystrophin Proteins 0.000 description 1
102000001039 Dystrophin Human genes 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
101900234631 Escherichia coli DNA polymerase I Proteins 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
102000001690 Factor VIII Human genes 0.000 description 1
108010054218 Factor VIII Proteins 0.000 description 1
240000000731 Fagus sylvatica Species 0.000 description 1
235000010099 Fagus sylvatica Nutrition 0.000 description 1
102000030914 Fatty Acid-Binding Human genes 0.000 description 1
101710145505 Fiber protein Proteins 0.000 description 1
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
102000004038 Glia Maturation Factor Human genes 0.000 description 1
108090000495 Glia Maturation Factor Proteins 0.000 description 1
102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
PABVKUJVLNMOJP-WHFBIAKZSA-N Glu-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(O)=O PABVKUJVLNMOJP-WHFBIAKZSA-N 0.000 description 1
KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 1
MUSGDMDGNGXULI-DCAQKATOSA-N Glu-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O MUSGDMDGNGXULI-DCAQKATOSA-N 0.000 description 1
WNRZUESNGGDCJX-JYJNAYRXSA-N Glu-Leu-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O WNRZUESNGGDCJX-JYJNAYRXSA-N 0.000 description 1
CBEUFCJRFNZMCU-SRVKXCTJSA-N Glu-Met-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O CBEUFCJRFNZMCU-SRVKXCTJSA-N 0.000 description 1
TWYSSILQABLLME-HJGDQZAQSA-N Glu-Thr-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O TWYSSILQABLLME-HJGDQZAQSA-N 0.000 description 1
MIWJDJAMMKHUAR-ZVZYQTTQSA-N Glu-Trp-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)O)N MIWJDJAMMKHUAR-ZVZYQTTQSA-N 0.000 description 1
VIPDPMHGICREIS-GVXVVHGQSA-N Glu-Val-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O VIPDPMHGICREIS-GVXVVHGQSA-N 0.000 description 1
JPXNYFOHTHSREU-UWVGGRQHSA-N Gly-Arg-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CN JPXNYFOHTHSREU-UWVGGRQHSA-N 0.000 description 1
DKEXFJVMVGETOO-LURJTMIESA-N Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CN DKEXFJVMVGETOO-LURJTMIESA-N 0.000 description 1
UWQDKRIZSROAKS-FJXKBIBVSA-N Gly-Met-Thr Chemical compound [H]NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UWQDKRIZSROAKS-FJXKBIBVSA-N 0.000 description 1
WNZOCXUOGVYYBJ-CDMKHQONSA-N Gly-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CN)O WNZOCXUOGVYYBJ-CDMKHQONSA-N 0.000 description 1
BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
WNGHUXFWEWTKAO-YUMQZZPRSA-N Gly-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN WNGHUXFWEWTKAO-YUMQZZPRSA-N 0.000 description 1
UVTSZKIATYSKIR-RYUDHWBXSA-N Gly-Tyr-Glu Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O UVTSZKIATYSKIR-RYUDHWBXSA-N 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
OHOXVDFVRDGFND-YUMQZZPRSA-N His-Cys-Gly Chemical compound N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CS)C(=O)NCC(O)=O OHOXVDFVRDGFND-YUMQZZPRSA-N 0.000 description 1
LBCAQRFTWMMWRR-CIUDSAMLSA-N His-Cys-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O LBCAQRFTWMMWRR-CIUDSAMLSA-N 0.000 description 1
CSTNMMIHMYJGFR-IHRRRGAJSA-N His-His-Arg Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C1=CN=CN1 CSTNMMIHMYJGFR-IHRRRGAJSA-N 0.000 description 1
102000006947 Histones Human genes 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
101000926939 Homo sapiens Glucocorticoid receptor Proteins 0.000 description 1
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
101000617808 Homo sapiens Synphilin-1 Proteins 0.000 description 1
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
241000701109 Human adenovirus 2 Species 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
241000484121 Human parvovirus Species 0.000 description 1
108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
101150032643 IVa2 gene Proteins 0.000 description 1
NKVZTQVGUNLLQW-JBDRJPRFSA-N Ile-Ala-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)O)N NKVZTQVGUNLLQW-JBDRJPRFSA-N 0.000 description 1
TZCGZYWNIDZZMR-UHFFFAOYSA-N Ile-Arg-Ala Natural products CCC(C)C(N)C(=O)NC(C(=O)NC(C)C(O)=O)CCCN=C(N)N TZCGZYWNIDZZMR-UHFFFAOYSA-N 0.000 description 1
BGZIJZJBXRVBGJ-SXTJYALSSA-N Ile-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N BGZIJZJBXRVBGJ-SXTJYALSSA-N 0.000 description 1
KTGFOCFYOZQVRJ-ZKWXMUAHSA-N Ile-Glu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O KTGFOCFYOZQVRJ-ZKWXMUAHSA-N 0.000 description 1
FCWFBHMAJZGWRY-XUXIUFHCSA-N Ile-Leu-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)O)N FCWFBHMAJZGWRY-XUXIUFHCSA-N 0.000 description 1
UWBDLNOCIDGPQE-GUBZILKMSA-N Ile-Lys Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN UWBDLNOCIDGPQE-GUBZILKMSA-N 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
102100037852 Insulin-like growth factor I Human genes 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
102000011782 Keratins Human genes 0.000 description 1
108010076876 Keratins Proteins 0.000 description 1
IBMVEYRWAWIOTN-UHFFFAOYSA-N L-Leucyl-L-Arginyl-L-Proline Natural products CC(C)CC(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O IBMVEYRWAWIOTN-UHFFFAOYSA-N 0.000 description 1
LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 1
241000880493 Leptailurus serval Species 0.000 description 1
BQSLGJHIAGOZCD-CIUDSAMLSA-N Leu-Ala-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 description 1
IBMVEYRWAWIOTN-RWMBFGLXSA-N Leu-Arg-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(O)=O IBMVEYRWAWIOTN-RWMBFGLXSA-N 0.000 description 1
KKXDHFKZWKLYGB-GUBZILKMSA-N Leu-Asn-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N KKXDHFKZWKLYGB-GUBZILKMSA-N 0.000 description 1
RIMMMMYKGIBOSN-DCAQKATOSA-N Leu-Asn-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O RIMMMMYKGIBOSN-DCAQKATOSA-N 0.000 description 1
PVMPDMIKUVNOBD-CIUDSAMLSA-N Leu-Asp-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O PVMPDMIKUVNOBD-CIUDSAMLSA-N 0.000 description 1
VWHGTYCRDRBSFI-ZETCQYMHSA-N Leu-Gly-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)NCC(O)=O VWHGTYCRDRBSFI-ZETCQYMHSA-N 0.000 description 1
VZBIUJURDLFFOE-IHRRRGAJSA-N Leu-His-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VZBIUJURDLFFOE-IHRRRGAJSA-N 0.000 description 1
DDEMUMVXNFPDKC-SRVKXCTJSA-N Leu-His-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CS)C(=O)O)N DDEMUMVXNFPDKC-SRVKXCTJSA-N 0.000 description 1
CSFVADKICPDRRF-KKUMJFAQSA-N Leu-His-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CN=CN1 CSFVADKICPDRRF-KKUMJFAQSA-N 0.000 description 1
NRFGTHFONZYFNY-MGHWNKPDSA-N Leu-Ile-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NRFGTHFONZYFNY-MGHWNKPDSA-N 0.000 description 1
IFMPDNRWZZEZSL-SRVKXCTJSA-N Leu-Leu-Cys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(O)=O IFMPDNRWZZEZSL-SRVKXCTJSA-N 0.000 description 1
RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 1
ZDJQVSIPFLMNOX-RHYQMDGZSA-N Leu-Thr-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N ZDJQVSIPFLMNOX-RHYQMDGZSA-N 0.000 description 1
DAYQSYGBCUKVKT-VOAKCMCISA-N Leu-Thr-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O DAYQSYGBCUKVKT-VOAKCMCISA-N 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
NFLFJGGKOHYZJF-BJDJZHNGSA-N Lys-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN NFLFJGGKOHYZJF-BJDJZHNGSA-N 0.000 description 1
JGAMUXDWYSXYLM-SRVKXCTJSA-N Lys-Arg-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O JGAMUXDWYSXYLM-SRVKXCTJSA-N 0.000 description 1
CIOWSLJGLSUOME-BQBZGAKWSA-N Lys-Asp Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O CIOWSLJGLSUOME-BQBZGAKWSA-N 0.000 description 1
YSZNURNVYFUEHC-BQBZGAKWSA-N Lys-Ser Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(O)=O YSZNURNVYFUEHC-BQBZGAKWSA-N 0.000 description 1
CAVRAQIDHUPECU-UVOCVTCTSA-N Lys-Thr-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAVRAQIDHUPECU-UVOCVTCTSA-N 0.000 description 1
CNXOBMMOYZPPGS-NUTKFTJISA-N Lys-Trp-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(O)=O CNXOBMMOYZPPGS-NUTKFTJISA-N 0.000 description 1
SQRLLZAQNOQCEG-KKUMJFAQSA-N Lys-Tyr-Ser Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CC=C(O)C=C1 SQRLLZAQNOQCEG-KKUMJFAQSA-N 0.000 description 1
WYEXWKAWMNJKPN-UBHSHLNASA-N Met-Ala-Phe Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCSC)N WYEXWKAWMNJKPN-UBHSHLNASA-N 0.000 description 1
QTZXSYBVOSXBEJ-WDSKDSINSA-N Met-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O QTZXSYBVOSXBEJ-WDSKDSINSA-N 0.000 description 1
RKIIYGUHIQJCBW-SRVKXCTJSA-N Met-His-Glu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O RKIIYGUHIQJCBW-SRVKXCTJSA-N 0.000 description 1
NLHSFJQUHGCWSD-PYJNHQTQSA-N Met-Ile-His Chemical compound N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC=N1)C(O)=O NLHSFJQUHGCWSD-PYJNHQTQSA-N 0.000 description 1
HGCNKOLVKRAVHD-RYUDHWBXSA-N Met-Phe Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-RYUDHWBXSA-N 0.000 description 1
OIFHHODAXVWKJN-ULQDDVLXSA-N Met-Phe-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 OIFHHODAXVWKJN-ULQDDVLXSA-N 0.000 description 1
SMVTWPOATVIXTN-NAKRPEOUSA-N Met-Ser-Ile Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O SMVTWPOATVIXTN-NAKRPEOUSA-N 0.000 description 1
QQPMHUCGDRJFQK-RHYQMDGZSA-N Met-Thr-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(C)C QQPMHUCGDRJFQK-RHYQMDGZSA-N 0.000 description 1
GWADARYJIJDYRC-XGEHTFHBSA-N Met-Thr-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O GWADARYJIJDYRC-XGEHTFHBSA-N 0.000 description 1
QYIGOFGUOVTAHK-ZJDVBMNYSA-N Met-Thr-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QYIGOFGUOVTAHK-ZJDVBMNYSA-N 0.000 description 1
101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 1
AUEJLPRZGVVDNU-UHFFFAOYSA-N N-L-tyrosyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-UHFFFAOYSA-N 0.000 description 1
NSTPXGARCQOSAU-VIFPVBQESA-N N-formyl-L-phenylalanine Chemical compound O=CN[C@H](C(=O)O)CC1=CC=CC=C1 NSTPXGARCQOSAU-VIFPVBQESA-N 0.000 description 1
AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
102000015336 Nerve Growth Factor Human genes 0.000 description 1
108010077850 Nuclear Localization Signals Proteins 0.000 description 1
102000007999 Nuclear Proteins Human genes 0.000 description 1
108010089610 Nuclear Proteins Proteins 0.000 description 1
108020003217 Nuclear RNA Proteins 0.000 description 1
102000043141 Nuclear RNA Human genes 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
101100350457 Oryza sativa subsp. japonica RR24 gene Proteins 0.000 description 1
108091081548 Palindromic sequence Proteins 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
PLNHHOXNVSYKOB-JYJNAYRXSA-N Phe-Arg-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=CC=C1)N PLNHHOXNVSYKOB-JYJNAYRXSA-N 0.000 description 1
BFYHIHGIHGROAT-HTUGSXCWSA-N Phe-Glu-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BFYHIHGIHGROAT-HTUGSXCWSA-N 0.000 description 1
WFHRXJOZEXUKLV-IRXDYDNUSA-N Phe-Gly-Tyr Chemical compound C([C@H](N)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 WFHRXJOZEXUKLV-IRXDYDNUSA-N 0.000 description 1
FXPZZKBHNOMLGA-HJWJTTGWSA-N Phe-Ile-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N FXPZZKBHNOMLGA-HJWJTTGWSA-N 0.000 description 1
IEOHQGFKHXUALJ-JYJNAYRXSA-N Phe-Met-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IEOHQGFKHXUALJ-JYJNAYRXSA-N 0.000 description 1
XQSREVQDGCPFRJ-STQMWFEESA-N Pro-Gly-Phe Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O XQSREVQDGCPFRJ-STQMWFEESA-N 0.000 description 1
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
108020005115 Pyruvate Kinase Proteins 0.000 description 1
102000013009 Pyruvate Kinase Human genes 0.000 description 1
108020005067 RNA Splice Sites Proteins 0.000 description 1
238000002123 RNA extraction Methods 0.000 description 1
208000035415 Reinfection Diseases 0.000 description 1
101100379247 Salmo trutta apoa1 gene Proteins 0.000 description 1
101100071627 Schizosaccharomyces pombe (strain 972 / ATCC 24843) swo1 gene Proteins 0.000 description 1
SSJMZMUVNKEENT-IMJSIDKUSA-N Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CO SSJMZMUVNKEENT-IMJSIDKUSA-N 0.000 description 1
HRNQLKCLPVKZNE-CIUDSAMLSA-N Ser-Ala-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O HRNQLKCLPVKZNE-CIUDSAMLSA-N 0.000 description 1
NLQUOHDCLSFABG-GUBZILKMSA-N Ser-Arg-Arg Chemical compound NC(N)=NCCC[C@H](NC(=O)[C@H](CO)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NLQUOHDCLSFABG-GUBZILKMSA-N 0.000 description 1
WDXYVIIVDIDOSX-DCAQKATOSA-N Ser-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CCCN=C(N)N WDXYVIIVDIDOSX-DCAQKATOSA-N 0.000 description 1
BLPYXIXXCFVIIF-FXQIFTODSA-N Ser-Cys-Arg Chemical compound C(C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CO)N)CN=C(N)N BLPYXIXXCFVIIF-FXQIFTODSA-N 0.000 description 1
GYDFRTRSSXOZCR-ACZMJKKPSA-N Ser-Ser-Glu Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O GYDFRTRSSXOZCR-ACZMJKKPSA-N 0.000 description 1
STIAINRLUUKYKM-WFBYXXMGSA-N Ser-Trp-Ala Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CO)=CNC2=C1 STIAINRLUUKYKM-WFBYXXMGSA-N 0.000 description 1
PZHJLTWGMYERRJ-SRVKXCTJSA-N Ser-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N)O PZHJLTWGMYERRJ-SRVKXCTJSA-N 0.000 description 1
HAYADTTXNZFUDM-IHRRRGAJSA-N Ser-Tyr-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O HAYADTTXNZFUDM-IHRRRGAJSA-N 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
108700025695 Suppressor Genes Proteins 0.000 description 1
102100021997 Synphilin-1 Human genes 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
FHDLKMFZKRUQCE-HJGDQZAQSA-N Thr-Glu-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FHDLKMFZKRUQCE-HJGDQZAQSA-N 0.000 description 1
MEJHFIOYJHTWMK-VOAKCMCISA-N Thr-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)O MEJHFIOYJHTWMK-VOAKCMCISA-N 0.000 description 1
VRUFCJZQDACGLH-UVOCVTCTSA-N Thr-Leu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VRUFCJZQDACGLH-UVOCVTCTSA-N 0.000 description 1
WNQJTLATMXYSEL-OEAJRASXSA-N Thr-Phe-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O WNQJTLATMXYSEL-OEAJRASXSA-N 0.000 description 1
NDZYTIMDOZMECO-SHGPDSBTSA-N Thr-Thr-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O NDZYTIMDOZMECO-SHGPDSBTSA-N 0.000 description 1
108700009124 Transcription Initiation Site Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
NXAPHBHZCMQORW-FDARSICLSA-N Trp-Arg-Ile Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O NXAPHBHZCMQORW-FDARSICLSA-N 0.000 description 1
TWJDQTTXXZDJKV-BPUTZDHNSA-N Trp-Arg-Ser Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O TWJDQTTXXZDJKV-BPUTZDHNSA-N 0.000 description 1
PMIJXCLOQFMOKZ-BPUTZDHNSA-N Trp-Asp-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N PMIJXCLOQFMOKZ-BPUTZDHNSA-N 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
108090000704 Tubulin Proteins 0.000 description 1
102000004243 Tubulin Human genes 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
DLZKEQQWXODGGZ-KWQFWETISA-N Tyr-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 DLZKEQQWXODGGZ-KWQFWETISA-N 0.000 description 1
HTHCZRWCFXMENJ-KKUMJFAQSA-N Tyr-Arg-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O HTHCZRWCFXMENJ-KKUMJFAQSA-N 0.000 description 1
JWHOIHCOHMZSAR-QWRGUYRKSA-N Tyr-Asp-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JWHOIHCOHMZSAR-QWRGUYRKSA-N 0.000 description 1
VFJIWSJKZJTQII-SRVKXCTJSA-N Tyr-Asp-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O VFJIWSJKZJTQII-SRVKXCTJSA-N 0.000 description 1
BVDHHLMIZFCAAU-BZSNNMDCSA-N Tyr-Cys-Phe Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O BVDHHLMIZFCAAU-BZSNNMDCSA-N 0.000 description 1
RWOKVQUCENPXGE-IHRRRGAJSA-N Tyr-Ser-Arg Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O RWOKVQUCENPXGE-IHRRRGAJSA-N 0.000 description 1
PLVVHGFEMSDRET-IHPCNDPISA-N Tyr-Ser-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CC=C(C=C3)O)N PLVVHGFEMSDRET-IHPCNDPISA-N 0.000 description 1
101710135104 Uncharacterized protein p6 Proteins 0.000 description 1
102000013127 Vimentin Human genes 0.000 description 1
108010065472 Vimentin Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
108010076324 alanyl-glycyl-glycine Proteins 0.000 description 1
KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 1
108010018691 arginyl-threonyl-arginine Proteins 0.000 description 1
108010068380 arginylarginine Proteins 0.000 description 1
238000000211 autoradiogram Methods 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
208000015294 blood coagulation disease Diseases 0.000 description 1
239000003914 blood derivative Substances 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
230000003915 cell function Effects 0.000 description 1
238000002659 cell therapy Methods 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical class ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
230000009852 coagulant defect Effects 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
108010004073 cysteinylcysteine Proteins 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000007547 defect Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
210000005045 desmin Anatomy 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
230000002900 effect on cell Effects 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
208000037828 epithelial carcinoma Diseases 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
229960000301 factor viii Drugs 0.000 description 1
108091022862 fatty acid binding Proteins 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
238000007380 fibre production Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000009432 framing Methods 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
108010050848 glycylleucine Proteins 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
108010036413 histidylglycine Proteins 0.000 description 1
108010025306 histidylleucine Proteins 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940100601 interleukin-6 Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
238000009940 knitting Methods 0.000 description 1
108010053037 kyotorphin Proteins 0.000 description 1
108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
108010073472 leucyl-prolyl-proline Proteins 0.000 description 1
108010091871 leucylmethionine Proteins 0.000 description 1
108010012058 leucyltyrosine Proteins 0.000 description 1
108010003700 lysyl aspartic acid Proteins 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
239000003471 mutagenic agent Substances 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
210000005044 neurofilament Anatomy 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
229940046166 oligodeoxynucleotide Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
102000003998 progesterone receptors Human genes 0.000 description 1
108090000468 progesterone receptors Proteins 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
101150066583 rep gene Proteins 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
102000003702 retinoic acid receptors Human genes 0.000 description 1
108090000064 retinoic acid receptors Proteins 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
231100000817 safety factor Toxicity 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
108010071207 serylmethionine Proteins 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
102000005969 steroid hormone receptors Human genes 0.000 description 1
108020003113 steroid hormone receptors Proteins 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
230000005945 translocation Effects 0.000 description 1
230000001228 trophic effect Effects 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
238000012795 verification Methods 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1
108090000195 villin Proteins 0.000 description 1
210000005048 vimentin Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10361—Methods of inactivation or attenuation
- C12N2710/10362—Methods of inactivation or attenuation by genetic engineering
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Virology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Immunology (AREA)
Hematology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Saccharide Compounds (AREA)

SK990-97A 1995-01-20 1996-01-19 Cells for the production of recombinant adenoviruses SK99097A3 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
FR9500747A FR2729674B1 (fr)	1995-01-20	1995-01-20	Cellules pour la production d'adenovirus recombinants
FR9506532A FR2741891B1 (fr)	1995-06-01	1995-06-01	Cellules pour la production d'adenovirus recombinants
FR9510541A FR2738575B1 (fr)	1995-09-08	1995-09-08	Cellules pour la production d'adenovirus recombinants
PCT/FR1996/000088 WO1996022378A1 (fr)	1995-01-20	1996-01-19	Cellules pour la production d'adenovirus recombinants

Publications (1)

Publication Number	Publication Date
SK99097A3 true SK99097A3 (en)	1998-02-04

Family

ID=27253011

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK990-97A SK99097A3 (en)	1995-01-20	1996-01-19	Cells for the production of recombinant adenoviruses

Country Status (15)

Country	Link
US (1)	US6127175A (de)
EP (1)	EP0805868A1 (de)
JP (1)	JPH11504502A (de)
KR (1)	KR100510822B1 (de)
AU (1)	AU717253B2 (de)
BR (1)	BR9606971A (de)
CA (1)	CA2210168A1 (de)
CZ (1)	CZ294969B6 (de)
FI (1)	FI973055L (de)
HU (1)	HU222191B1 (de)
IL (1)	IL116816A (de)
MX (1)	MX9704552A (de)
NO (1)	NO320382B1 (de)
SK (1)	SK99097A3 (de)
WO (1)	WO1996022378A1 (de)

Families Citing this family (390)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0710288B1 (de) *	1993-06-10	2006-04-05	Genetic Therapy, Inc.	Adenovirale vektoren für die behandlung der hämophilie
ATE336587T1 (de) *	1994-06-10	2006-09-15	Genvec Inc	Adenoviren-vektor systeme und zelllinien
US6281010B1 (en)	1995-06-05	2001-08-28	The Trustees Of The University Of Pennsylvania	Adenovirus gene therapy vehicle and cell line
US5756283A (en) *	1995-06-05	1998-05-26	The Trustees Of The University Of Pennsylvania	Method for improved production of recombinant adeno-associated viruses for gene therapy
US6004797A (en) *	1995-11-09	1999-12-21	Avigen, Inc.	Adenovirus helper-free recombinant AAV Virion production
US6730662B1 (en)	1996-07-05	2004-05-04	Mcgill University	Adenovirus E4 proteins for inducing cell death
DE69725882T2 (de) *	1996-07-05	2004-07-29	Branton, Philip E., St. Lambert	Adenovirus e4 proteine für induktion von zelltod
US7232899B2 (en)	1996-09-25	2007-06-19	The Scripps Research Institute	Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
EP0937150A2 (de) *	1996-09-25	1999-08-25	Novartis AG	Verpackungszellinien in der verwendung zur erleichterung der entwicklung hocheffizienter adenoviraler vektoren
US6544769B1 (en)	1996-12-13	2003-04-08	Schering Corporation	Compostions comprising viruses and methods for concentrating virus preparations
US6261823B1 (en)	1996-12-13	2001-07-17	Schering Corporation	Methods for purifying viruses
US6146891A (en)	1997-01-31	2000-11-14	Schering Corporation	Methods for cultivating cells and propagating viruses
US6168944B1 (en)	1997-01-31	2001-01-02	Schering Corporation	Methods for cultivating cells and propagating viruses
CA2283253A1 (en) *	1997-03-04	1998-09-11	Baxter International Inc.	Adenovirus e1-complementing cell lines
WO1998049321A2 (en)	1997-04-28	1998-11-05	Rhone-Poulenc Rorer S.A.	Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
WO1998059063A2 (en)	1997-06-23	1998-12-30	University Of Saskatchewan	Bovine adenovirus type 3 genome
EP1049767B1 (de)	1998-01-08	2005-08-17	Aventis Pharmaceuticals Inc.	Transgenes kaninchen, dass ein funktionelles menschliches lipoprotein(a) exprimiert
CA2319212A1 (en) *	1998-02-17	1999-08-19	Genzyme Corporation	Methods for purified aav vector production
FR2777570A1 (fr) *	1998-04-17	1999-10-22	Transgene Sa	Mutant ayant une activite phosphoribosyl transferase
US6225456B1 (en)	1998-05-07	2001-05-01	University Technololy Corporation	Ras suppressor SUR-5
US6506889B1 (en)	1998-05-19	2003-01-14	University Technology Corporation	Ras suppressor SUR-8 and related compositions and methods
GB9811171D0 (en) *	1998-05-22	1998-07-22	Royal Free Hosp School Med	Viral vector
GB9811172D0 (en) *	1998-05-22	1998-07-22	Royal Free Hosp School Med	Virus production
US6458586B1 (en)	1998-11-02	2002-10-01	University Of Saskatchewan	Bovine cells expressing adenovirus essential functions for propagation of recombinant adenoviral vectors
US6441156B1 (en) *	1998-12-30	2002-08-27	The United States Of America As Represented By The Department Of Health And Human Services	Calcium channel compositions and methods of use thereof
US8114850B2 (en)	1999-04-08	2012-02-14	Advanced Cancer Therapeutics, Llc	Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
JP2002541264A (ja)	1999-04-08	2002-12-03	ユーエイビー・リサーチ・ファウンデーション	冨ｇオリゴヌクレオチドの抗増殖活性およびヌクレオリンに結合するためのその使用方法
US7960540B2 (en)	1999-04-08	2011-06-14	Advanced Cancer Therapeutics, Llc	Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
FR2794771B1 (fr)	1999-06-11	2001-08-10	Aventis Pharma Sa	Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
PT1290023E (pt)	2000-03-31	2011-01-05	Aventis Pharma Inc	Factor indutor do factor nuclear kb
GB0018307D0 (en)	2000-07-26	2000-09-13	Aventis Pharm Prod Inc	Polypeptides
US7198924B2 (en)	2000-12-11	2007-04-03	Invitrogen Corporation	Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
DE10044384A1 (de) *	2000-09-08	2002-04-18	Medigene Ag	Wirtszellen zur Verpackung von rekombinantem Adeno-assoziiertem Virus (rAAV), Verfahren zu ihrer Herstellung und deren Verwendung
WO2002053761A2 (en)	2000-12-28	2002-07-11	Wyeth	Recombinant protective protein from $i(streptococcus pneumoniae)
AUPR518501A0 (en)	2001-05-22	2001-06-14	Unisearch Limited	Yin yang-1
US6677156B2 (en)	2001-07-23	2004-01-13	Genvec, Inc.	Non-adenoviral gene product-based complementing cells for adenoviral vectors
US6682929B2 (en)	2001-07-23	2004-01-27	Genvec, Inc.	Adenovector complementing cells
US7647184B2 (en) *	2001-08-27	2010-01-12	Hanall Pharmaceuticals, Co. Ltd	High throughput directed evolution by rational mutagenesis
US20030129203A1 (en) *	2001-08-27	2003-07-10	Nautilus Biotech S.A.	Mutant recombinant adeno-associated viruses
AU2002332736A1 (en) *	2001-08-30	2003-03-18	The Government Of The United States Of America, As Represented By The Secretary Of The Department Of	New adenovirus type 7 vectors
US20040023910A1 (en) *	2001-09-28	2004-02-05	Zhiming Zhang	Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
MX339524B (es)	2001-10-11	2016-05-30	Wyeth Corp	Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US20030224404A1 (en) *	2002-02-25	2003-12-04	Manuel Vega	High throughput directed evolution of nucleic acids by rational mutagenesis
EP1497440B1 (de) *	2002-04-25	2008-08-20	Crucell Holland B.V.	Stabile adenovirale vektoren und methoden für deren vermehrung
EP1997913A1 (de)	2002-05-15	2008-12-03	Integragen	Menschliches Adipositas-Suszeptibilitäsgen und Verwendungen davon
EP1506286B1 (de)	2002-05-24	2014-03-19	Merck Sharp & Dohme Corp.	Neutralisierung eines menschlichen anti-igfr-antikörpers
US20040106194A1 (en) *	2002-08-22	2004-06-03	Bett Andrew J.	Methods for propagating adenovirus and virus produced thereby
US20050202438A1 (en) *	2002-09-09	2005-09-15	Rene Gantier	Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US20060020396A1 (en) *	2002-09-09	2006-01-26	Rene Gantier	Rational directed protein evolution using two-dimensional rational mutagenesis scanning
DE60332358D1 (de) *	2002-09-09	2010-06-10	Hanall Pharmaceutical Co Ltd	Protease-resistente modifizierte interferon alpha polypeptide
US20080124360A1 (en)	2003-01-24	2008-05-29	Seggern Daniel J Von	Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
WO2005017149A1 (en) *	2003-06-03	2005-02-24	Cell Genesys, Inc.	Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US7186699B2 (en) *	2003-06-03	2007-03-06	Cell Genesys, Inc.	Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US7485291B2 (en) *	2003-06-03	2009-02-03	Cell Genesys, Inc.	Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
WO2005012537A2 (en) *	2003-07-25	2005-02-10	Genvec, Inc.	Adenoviral vector-based vaccines
DE602004021186D1 (de)	2003-08-22	2009-07-02	Integragen Sa	Menschliches autismus-suszeptibilitätsgen und verwendungen davon
DE602004025726D1 (de)	2003-11-14	2010-04-08	Genvec Inc	Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
WO2005054438A2 (en)	2003-12-01	2005-06-16	Invitrogen Corporation	Nucleic acid molecules containing recombination sites and methods of using the same
DE602005017743D1 (de) *	2004-01-23	2009-12-31	Angeletti P Ist Richerche Bio	Impfstoffträger für schimpansen-adenovirus
US7432057B2 (en)	2004-01-30	2008-10-07	Michigan State University	Genetic test for PSE-susceptible turkeys
AU2005243730B2 (en)	2004-04-12	2010-05-27	Genvec, Inc.	Method of using adenoviral vectors to induce an immune response
ATE424469T1 (de)	2004-07-01	2009-03-15	Integragen Sa	Für prkcb1 kodierendes humanes autismus- suszeptibilitätsgen und dessen verwendung
US7604798B2 (en)	2004-07-15	2009-10-20	Northwestern University	Methods and compositions for importing nucleic acids into cell nuclei
AU2005274948B2 (en)	2004-07-16	2011-09-22	Genvec, Inc.	Vaccines against aids comprising CMV/R-nucleic acid constructs
EP1784493A2 (de) *	2004-09-01	2007-05-16	The Government of the United States of America as Represented by The Department of Health and Human Services	Adenovirale vektoren mit der fähigkeit zum umwandeln von apcs, mögliche verwendung bei immunantworterzeugung
US20060057127A1 (en) *	2004-09-10	2006-03-16	Pocheng Liu	Cytokine-expressing cellular vaccines for treatment of prostate cancer
DE602006017045D1 (de)	2005-03-24	2010-11-04	Integragen Sa	Ein transmembranprotein kodierendes humanes autismus-suszeptibilitätsgen und dessen verwendung
US20060234347A1 (en) *	2005-04-13	2006-10-19	Harding Thomas C	Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
CA2609142C (en)	2005-05-27	2016-02-09	Fondazione Centro San Raffaele Del Monte Tabor	Therapeutic gene vectors comprising mirna target sequences
MX2008000985A (es)	2005-07-21	2008-04-07	Abbott Lab	Expresion de gen multiple que incluye construcciones y metodos sorf (cuadro de lectura abierta simple) con poliproteinas, pro-proteinas y proteolisis.
BRPI0615400A2 (pt)	2005-08-31	2011-05-17	Genvec Inc	vacinas para malária baseadas em vetor adenoviral
US9651543B2 (en)	2005-08-31	2017-05-16	The United States Of America As Represented By The Secretary Of The Navy	Malaria antigen screening method
US8450055B2 (en) *	2005-08-31	2013-05-28	The United States Of America As Represented By The Secretary Of The Navy	Malaria antigen screening method
BRPI0618441B8 (pt)	2005-11-10	2021-07-27	Genvec Inc	vetor adenoviral
WO2007104792A2 (en) *	2006-03-16	2007-09-20	Crucell Holland B.V.	Recombinant adenoviruses based on serotype 26 and 48, and use thereof
EP1835036A1 (de)	2006-03-16	2007-09-19	Exonhit Therapeutics SA	Zusammensetzungen und Methoden zur Nachweis und Behandlung von Krebs
PL2829551T3 (pl)	2006-10-19	2018-04-30	Csl Limited	Antagonisty przeciwciała o wysokim powinowactwie wobec receptora alfa 1 interleukiny-13
AU2007319605B2 (en)	2006-10-19	2011-02-17	Csl Limited	Anti-IL-13R alpha 1 antibodies and their uses thereof
AR064642A1 (es)	2006-12-22	2009-04-15	Wyeth Corp	Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
US20080248060A1 (en) *	2007-01-09	2008-10-09	Genvec, Inc.	Adenoviral vector-based malaria vaccines
EP2027868A1 (de)	2007-08-24	2009-02-25	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Verwendung von SCO-Spondin zur Hemmung oder Verhinderung von durch Zelltod-Rezeptor-Liganden vermittelter Apoptose
EP2238170B1 (de)	2008-01-31	2016-11-23	INSERM - Institut National de la Santé et de la Recherche Médicale	Antikörper gegen humanes cd39 und ihre verwendung zur hemmung der regulatorischen t-zell-aktivität
WO2010040766A1 (en)	2008-10-07	2010-04-15	INSERM (Institut National de la Santé et de la Recherche Médicale)	Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (pf4v1)
MX2011004755A (es)	2008-11-05	2011-10-10	Wyeth Llc	Composicion inmunogenica multicomponente para la prevencion de enfermedad estreptococica beta-hemolitica (bhs).
EP2199387A1 (de)	2008-12-19	2010-06-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	Serinproteasederivate und deren Verwendung zur Vorbeugung und/oder Behandlung von Blutgerinnungsstörungen
JP5833448B2 (ja)	2008-12-19	2015-12-16	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	セリンプロテアーゼ誘導体および血液凝固疾患の予防または処置における使用
AU2010206195B2 (en)	2009-01-20	2016-03-10	Transgene Sa	Soluble ICAM-1 as biomarker for prediction of therapeutic response
WO2010096561A1 (en)	2009-02-18	2010-08-26	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Synthetic hiv/siv gag proteins and uses thereof
EP3002296B1 (de)	2009-03-17	2020-04-29	Université d'Aix-Marseille	Btla-antikörper und ihre verwendung
ES2555858T3 (es)	2009-03-24	2016-01-11	Transgene Sa	Biomarcador para el control de pacientes
PL2419728T3 (pl)	2009-04-17	2014-05-30	Transgene Sa	Biomarker do monitorowania pacjentów
EP2427205A2 (de)	2009-05-04	2012-03-14	INSERM - Institut National de la Santé et de la Recherche Médicale	Par2-agonisten zur verwendung bei der behandlung oder prävention von infektionen mit dem grippevirus typ a
EP2427497B1 (de)	2009-05-07	2016-12-07	Stallergenes	Verwendung von igg1-immunoglobulinen und/oder liganden des cd32-rezeptors zur behandlung entzündlicher krankheiten und ereignisse über die schleimhaut
US9050276B2 (en)	2009-06-16	2015-06-09	The Trustees Of Columbia University In The City Of New York	Autism-associated biomarkers and uses thereof
CN102483405B (zh)	2009-07-10	2015-12-02	特朗斯吉有限公司	用于选择患者的生物标志物及相关方法
US20120219583A1 (en)	2009-10-16	2012-08-30	Los Alamos National Security, Llc	Nucleic acid sequences encoding expandable hiv mosaic proteins
WO2011048443A1 (en)	2009-10-20	2011-04-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Neuronal exocytosis inhibiting peptides derived from c subunit of v-atpase and cosmetic and pharmaceutical compositions containing said peptides
WO2011053699A1 (en)	2009-10-30	2011-05-05	Abbott Laboratories	Sorf constructs and multiple gene expression
KR20120139672A (ko)	2009-11-09	2012-12-27	젠벡, 인코포레이티드	원숭이 아데노바이러스 벡터의 증식 방법
WO2011057254A2 (en)	2009-11-09	2011-05-12	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Simian adenoviral vector-based vaccines
WO2011080322A1 (en)	2009-12-30	2011-07-07	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Method of prognosing the outcome of acquired hemophilia and of treatment of hemophilia
US8735171B2 (en)	2010-01-13	2014-05-27	Institut National De La Santé Et De La Recherche Médicale (Inserm)	Promyelocytic leukemia protein as a redox sensor
KR20110103119A (ko) *	2010-03-12	2011-09-20	국립암센터	신규한 조건부-복제 가능 아데노바이러스 및 그의 제조 방법
EP2547362B1 (de)	2010-03-17	2021-08-25	Cornell University	Unterbrochener impfstoff auf adenovirusbasis gegen drogenmissbrauch
LT2555789T (lt)	2010-04-08	2020-09-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Inhibuojantys peptidai, kilę iš trem tipo transkripto 1 (tlt-1), ir jų naudojimas
EP2575853B1 (de)	2010-05-25	2016-08-24	INSERM - Institut National de la Santé et de la Recherche Médicale	Verfahren und pharmazeutische zusammensetzung zur behandlung einer frühzeitigen nahrungsaufnahmestörung bei einem patienten
EP2590669B1 (de)	2010-07-09	2016-08-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	Behandlung von krankheiten im zusammenhang mit degenerativen netzhautstörungen
US9040671B2 (en)	2010-07-23	2015-05-26	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Methods for cancer management targeting Co-029
WO2012021730A2 (en)	2010-08-11	2012-02-16	Genvec, Inc.	Respiratory syncytial virus (rsv) vaccine
CN107913396B (zh)	2010-08-23	2022-03-08	惠氏有限责任公司	脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
AU2011300409B2 (en)	2010-09-10	2015-03-26	Wyeth Llc	Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
US9132173B2 (en)	2010-10-15	2015-09-15	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Expression vector for cholesterol 24-hydrolase in therapy of Huntington's disease
WO2012080769A1 (en)	2010-12-15	2012-06-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anti-cd277 antibodies and uses thereof
WO2012083297A2 (en)	2010-12-17	2012-06-21	Genvec, Inc.	Adenoviral vectors with modified hexon regions
WO2012088041A1 (en)	2010-12-20	2012-06-28	Genvec, Inc.	Adenoviral vector-based dengue fever vaccine
EP2654789B1 (de)	2010-12-22	2018-05-30	Orega Biotech	Antikörper gegen humanes cd39 und ihre verwendung
EP2658869B1 (de)	2010-12-30	2019-06-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antigenbindende formate zur verwendung in therapeutischen behandlungen oder diagnosetests
WO2012101125A1 (en)	2011-01-24	2012-08-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	Specific antibodies against human cxcl4 and uses thereof
WO2012120131A1 (en)	2011-03-09	2012-09-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for generating cell microparticles
WO2012120129A1 (en)	2011-03-10	2012-09-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical composition for the treatment of infectious diseases
EP3147297B1 (de)	2011-03-31	2018-12-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Gegen icos gerichtete antikörper und verwendungen davon
NO2707391T3 (de)	2011-05-13	2018-04-07
JP2014516960A (ja)	2011-05-19	2014-07-17	インサーム（インスティテュナシオナルドゥラサンテエドゥラルシェルシェメディカル）	抗ヒトｈｅｒ３抗体及びその使用
WO2012162428A1 (en)	2011-05-23	2012-11-29	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Prime-boost vaccination for viral infection
JP6166258B2 (ja)	2011-06-15	2017-07-19	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	ブレビバクテリウム・オーランチアカム（Ｂｒｅｖｉｂａｃｔｅｒｉｕｍａｕｒａｎｔｉａｃｕｍ）から単離されたポリペプチド及び癌の治療を目的とするその使用
ES2677367T3 (es)	2011-06-22	2018-08-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anticuerpos anti-Axl y usos de los mismos
CA2839508A1 (en)	2011-06-22	2012-12-27	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Anti-axl antibodies and uses thereof
EP2543677A1 (de)	2011-07-08	2013-01-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antikörper zur Behandlung und Vorbeugung von Thrombose
EP2543678A1 (de)	2011-07-08	2013-01-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antikörper zur Behandlung und Vorbeugung von Thrombose
EP2543679A1 (de)	2011-07-08	2013-01-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antikörper zur Behandlung und Vorbeugung von Thrombose
FR2979346B1 (fr)	2011-08-23	2013-09-27	Univ Joseph Fourier	Nanocorps anti-vcam-1
US20140235492A1 (en)	2011-09-20	2014-08-21	Institut National De La Sante Et De La Recherche Medicate (Inserm)	Methods for preparing single domain antibody microarrays
CN103987726B (zh)	2011-10-05	2017-10-03	金维克有限公司	猴(大猩猩)腺病毒或腺病毒载体及其使用方法
WO2013052859A2 (en)	2011-10-05	2013-04-11	Genvec, Inc.	Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
JP6757120B2 (ja)	2011-10-05	2020-09-16	ジェンヴェックエルエルシー	アーフェンアデノウイルス（ゴリラ）又はアデノウイルスベクター、及び使用方法
US9233153B2 (en)	2011-10-05	2016-01-12	Genvec, Inc.	Affenadenovirus (gorilla) or adenoviral vectors and methods of use
WO2013116591A1 (en)	2012-02-02	2013-08-08	Genvec, Inc.	Adenoviral vector-based malaria vaccine
JP6188728B2 (ja)	2012-02-07	2017-08-30	グローバル・バイオ・セラピューティクス・インコーポレイテッドＧｌｏｂａｌＢｉｏＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	核酸送達の区画化方法ならびにその組成物および使用
SA115360586B1 (ar)	2012-03-09	2017-04-12	فايزر انك	تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY198910A (en)	2012-03-09	2023-10-02	Pfizer	Neisseria meningitidis compositions and methods thereof
WO2013139861A1 (en)	2012-03-20	2013-09-26	Luc Montagnier	Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
WO2013174835A1 (en)	2012-05-22	2013-11-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for screening a candidate compound for its pharmacology on a nuclear receptor
EP2855678B1 (de)	2012-05-25	2017-08-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verfahren zur auswahl von bindemitteln mittels phagendisplay und maskierter auswahl
HK1210475A1 (en)	2012-05-29	2016-04-22	Genvec, Inc.	Herpes simplex virus vaccine
WO2013181128A1 (en)	2012-05-29	2013-12-05	Genvec, Inc.	Modified serotype 28 adenoviral vectors
WO2014001368A1 (en)	2012-06-25	2014-01-03	Orega Biotech	Il-17 antagonist antibodies
EP2692732A1 (de)	2012-08-03	2014-02-05	Stallergenes S.A.	Neues Allergen aus Kreuzkrautpollen und Verwendung davon
US9695247B2 (en)	2012-09-03	2017-07-04	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Antibodies directed against ICOS for treating graft-versus-host disease
AU2013311606B2 (en)	2012-09-07	2017-10-05	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (TREM-1) Trem-Like Transcript 1 (TLT-1) and uses thereof
WO2014043518A1 (en)	2012-09-14	2014-03-20	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
KR101522341B1 (ko) *	2012-10-02	2015-05-21	국립암센터	신규한 조건부-복제 가능 아데노바이러스 및 그의 제조 방법
AU2013328550B2 (en)	2012-10-12	2017-10-05	University Of Leicester	CSN5 polypeptides and uses thereof for screening therapeutic agents
EP2733153A1 (de)	2012-11-15	2014-05-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verfahren zur Herstellung von Immunkonjugaten und Verwendungen davon
DK3199552T3 (da)	2012-11-20	2020-03-30	Sanofi Sa	Anti-ceacam5-antistoffer og anvendelser heraf
US11013783B2 (en)	2012-12-26	2021-05-25	Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement	Anti-inflammatory peptides and methods for treating inflammatory diseases
EP2749289A1 (de)	2012-12-26	2014-07-02	Institut National De La Recherche Agronomique (INRA)	Entzündungshemmende Peptide
HK1210713A1 (en)	2012-12-27	2016-05-06	Sanofi	Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
WO2014107739A1 (en)	2013-01-07	2014-07-10	Eleven Biotherapeutics, Inc.	Antibodies against pcsk9
US9066966B2 (en)	2013-02-01	2015-06-30	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Methods and pharmaceutical compositions for the treatment of cardiomyopathy due to friedreich ataxia
WO2014136064A2 (en)	2013-03-08	2014-09-12	Pfizer Inc.	Immunogenic fusion polypeptides
WO2014164703A1 (en)	2013-03-11	2014-10-09	University Of Florida Research Foundation, Inc.	Delivery of card protein as therapy for occular inflammation
EP2970398B1 (de)	2013-03-13	2024-05-08	The United States of America, as Represented by The Secretary, Department of Health and Human Services	Rsv-f-prefusionsproteine und deren verwendung
DE102013004595A1 (de)	2013-03-15	2014-09-18	Emergent Product Development Germany Gmbh	RSV-Impfstoffe
KR101606910B1 (ko)	2013-03-29	2016-04-04	충북보건과학대학교 산학협력단	아데노바이러스 벡터 생산용 ａ５４９ 기반 세포주
WO2014207173A1 (en)	2013-06-27	2014-12-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	Interleukin 15 (il-15) antagonists and uses thereof for the treatment of autoimmune diseases and inflammatory diseases
EP2824176A1 (de)	2013-07-11	2015-01-14	Siamed'xpress	Verfahren zur Herstellung von sialylierten therapeutischen Proteinen
HK1225258B (en)	2013-08-08	2017-09-08	Global Bio Therapeutics, Inc.	Clamping device for minimally invasive surgery
RU2662968C2 (ru)	2013-09-08	2018-07-31	Пфайзер Инк.	Иммуногенная композиция против neisseria meningitidis (варианты)
JP2016537995A (ja)	2013-11-05	2016-12-08	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	新しいアルツハイマー病動物モデル
CN105849125B (zh)	2013-11-07	2020-05-15	国家医疗保健研究所	神经调节蛋白变构抗her3抗体
RU2677997C2 (ru)	2014-01-20	2019-01-22	Санофи	Новый полипептид системы цитохрома р450 с повышенной ферментной активностью
US11053291B2 (en)	2014-02-19	2021-07-06	University Of Florida Research Foundation, Incorporated	Delivery of Nrf2 as therapy for protection against reactive oxygen species
US10544231B2 (en)	2014-04-16	2020-01-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antibodies for the prevention or the treatment of bleeding episodes
FR3020063A1 (fr)	2014-04-16	2015-10-23	Gamamabs Pharma	Anticorps humain anti-her4
ES2796857T3 (es)	2014-04-17	2020-11-30	Inst Nat Sante Rech Med	Polipéptidos y usos de los mismos para reducir la motilidad celular mediada por CD95
FR3021970B1 (fr)	2014-06-06	2018-01-26	Universite Sciences Technologies Lille	Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
EP2974735A1 (de)	2014-07-15	2016-01-20	Institut National De La Recherche Agronomique (INRA)	Entzündungshemmende Eigenschaften eines Oberflächenproteins aus Propionibakterium freudenreichii
WO2016037154A1 (en)	2014-09-04	2016-03-10	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Recombinant hiv-1 envelope proteins and their use
WO2016077687A1 (en)	2014-11-14	2016-05-19	Voyager Therapeutics, Inc.	Compositions and methods of treating amyotrophic lateral sclerosis (als)
JP6864953B2 (ja)	2014-12-09	2021-04-28	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	Ａｘｌに対するヒトモノクローナル抗体
WO2016103238A1 (en)	2014-12-24	2016-06-30	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Recombinant metapneumovirus f proteins and their use
DK3247388T3 (da)	2015-01-20	2025-12-22	Us Health	Rekombinant human/bovin parainfluenzavirus 3 (b/hpiv3), der udtrykker et kimærisk rsv/bpiv3 f-protein, og anvendelser deraf
CN120988137A (zh)	2015-01-23	2025-11-21	赛诺菲	抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
WO2016132294A1 (en)	2015-02-19	2016-08-25	Pfizer Inc.	Neisseria meningitidis compositions and methods thereof
WO2016138160A1 (en)	2015-02-24	2016-09-01	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
WO2016135041A1 (en)	2015-02-26	2016-09-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Fusion proteins and antibodies comprising thereof for promoting apoptosis
US11040113B2 (en)	2015-03-23	2021-06-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical composition for the treatment and the prevention of neurological phenotype associated with Friedreich ataxia
EP3091033A1 (de)	2015-05-06	2016-11-09	Gamamabs Pharma	Anti-human-her3-antikörper und verwendungen davon
US20180125947A1 (en)	2015-05-20	2018-05-10	INSERM (Institut National de la Santé et de la Recherche Médicale)	Treatment of retinal detachment
WO2016188911A1 (en)	2015-05-22	2016-12-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Human monoclonal antibodies fragments inhibiting both the cath-d catalytic activity and its binding to the lrp1 receptor
JP2018525029A (ja)	2015-07-07	2018-09-06	インセルム（インスティチュートナショナルデラサンテエデラリシェルシェメディカル）	ミオシン１８ａに対する特異性を有する抗体およびその使用
EP4137150A1 (de)	2015-08-03	2023-02-22	The United States of America, as represented by the Secretary, Department of Health and Human Services	Brachyury-deletionsmutanten, nichthefevektoren zur codierung von brachyury-deletionsmutanten und verwendung davon
WO2017029391A1 (en)	2015-08-20	2017-02-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	New method for treating cancer
WO2017046200A1 (en)	2015-09-16	2017-03-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	Specific interleukin-15 (il-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases
DK3353196T5 (da)	2015-09-22	2024-09-30	Inst Nat Sante Rech Med	Polypeptider, der er i stand til at inhibere bindingen mellem leptin og neuropilin-1
KR20180063885A (ko)	2015-09-24	2018-06-12	더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐	전이 감소를 위한 방법 및 조성물
WO2017050955A1 (en)	2015-09-24	2017-03-30	INSERM (Institut National de la Santé et de la Recherche Médicale)	Agents capable of inhibiting the binding between leptin and vegf165
PT3405215T (pt)	2016-01-19	2022-09-20	Univ California	Métodos para o tratamento da doença de danon e outros transtornos da autofagia
WO2017139392A1 (en)	2016-02-08	2017-08-17	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Recombinant hiv-1 envelope proteins and their use
MX2018010295A (es)	2016-02-26	2019-06-06	Inst Nat Sante Rech Med	Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
US10808011B2 (en)	2016-03-09	2020-10-20	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Recombinant HIV-1 envelope proteins and their use
GB201604458D0 (en)	2016-03-16	2016-04-27	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against cancers
CN109641955B (zh)	2016-03-22	2022-07-08	国家医疗保健研究所	人源化抗claudin-1抗体及其用途
FI3436593T3 (fi)	2016-03-28	2023-03-16	Ultragenyx Pharmaceutical Inc	Adenoviruksen lämpöinaktivointimenetelmiä
WO2018013705A1 (en) *	2016-07-12	2018-01-18	Dimension Therapeutics	Use of glucocorticoid analogs to enhance recombinant adeno-associated virus yield
TWI790206B (zh)	2016-07-18	2023-01-21	法商賽諾菲公司	特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
ES3041722T3 (en)	2016-07-29	2025-11-14	Inst Nat Sante Rech Med	Antibodies targeting tumor associated macrophages and uses thereof
US20200165302A1 (en)	2016-09-14	2020-05-28	Université Catholique de Louvain	Modified vsv-g and vaccines thereof
NZ751966A (en)	2016-09-20	2023-03-31	Boehringer Ingelheim Vetmedica Gmbh	New promoters
WO2018057441A1 (en)	2016-09-20	2018-03-29	Boehringer Ingelheim Vetmedica Gmbh	Canine adenovirus vectors
MX2019003161A (es)	2016-09-20	2019-05-27	Boehringer Ingelheim Vetmedica Gmbh	Nuevo sitio de insercion orf70 de ehv.
CA3036310A1 (en)	2016-09-20	2018-03-29	Boehringer Ingelheim Vetmedica Gmbh	New swine influenza vaccine
WO2018064523A1 (en)	2016-09-30	2018-04-05	Genvec, Inc.	Adenovectors for delivery of therapeutic genetic material into t cells
WO2018067582A2 (en)	2016-10-03	2018-04-12	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Hiv-1 env fusion peptide immunogens and their use
PL3526321T3 (pl)	2016-10-14	2025-04-28	Ultragenyx Pharmaceutical Inc.	Zastosowanie środków regulujących ciśnienie osmotyczne w celu zwiększenia wydajności rekombinacyjnego wirusa związanego z adenowirusami
TW202300515A (zh)	2016-10-20	2023-01-01	法商賽諾菲公司	抗ｃｈｉｋｖ抗體及其用途
CA3080270A1 (en)	2016-10-25	2018-05-03	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Monoclonal antibodies binding to the cd160 transmembrane isoform
US10960070B2 (en)	2016-10-25	2021-03-30	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Prefusion coronavirus spike proteins and their use
FR3058143B1 (fr)	2016-10-27	2021-03-12	Univ Grenoble Alpes	Nanocorps anti-tau
WO2018089527A1 (en)	2016-11-09	2018-05-17	Intrexon Corporation	Frataxin expression constructs
US11084850B2 (en)	2016-12-16	2021-08-10	The Pirbright Institute	Recombinant prefusion RSV F proteins and uses thereof
JP7618386B2 (ja)	2017-01-30	2025-01-21	ブレインヴェクティス	ポリグルタミン反復脊髄小脳失調症の処置におけるコレステロール２４－ヒドロキシラーゼ（ｈｙｄｒｏｌａｓｅ）のための発現ベクター
AU2018215585B2 (en)	2017-01-31	2022-03-17	Pfizer Inc.	Neisseria meningitidis compositions and methods thereof
CN110392697A (zh)	2017-03-02	2019-10-29	国家医疗保健研究所	对nectin-4具有特异性的抗体及其用途
IL269150B2 (en)	2017-03-16	2025-04-01	Innate Pharma	Cancer treatment preparations and methods
WO2018175775A1 (en)	2017-03-22	2018-09-27	Dimension Therapeutics	Cell culture methods involving hdac inhibitors or rep proteins
US11235056B2 (en)	2017-03-24	2022-02-01	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Glycan-masked engineered outer domains of HIV-1 gp120 and their use
WO2018178051A1 (en)	2017-03-28	2018-10-04	INSERM (Institut National de la Santé et de la Recherche Médicale)	Scgb1a1 polymorphism for the prediction and therapy or prevention of primary graft dysfunction
EP3388072A1 (de)	2017-04-10	2018-10-17	Universität Leipzig	Ubichinonunabhängige cytoplasmische dihydroorotat-dehydrogenase zur verwendung als arzneimittel
WO2018208960A1 (en)	2017-05-09	2018-11-15	Dimension Therapeutics, Inc.	Scalable method for producing transfection reagents
FI3638776T3 (fi)	2017-06-14	2025-12-09	Univ Dresden Tech	Menetelmiä ja välineitä genomien geneettiseen muokkaamiseen hyödyntäen suunnittelu-DNA:ta rekombinoivia entsyymejä
US11174322B2 (en)	2017-07-24	2021-11-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antibodies and peptides to treat HCMV related diseases
WO2019038420A1 (en)	2017-08-25	2019-02-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OSTEOCLAST DISEASES
KR102764182B1 (ko)	2017-09-21	2025-02-07	임체크 테라퓨틱스	Ｂｔｎ２에 대해 특이성을 갖는 항체 및 이의 용도
WO2019079337A1 (en)	2017-10-16	2019-04-25	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE
EP3697908A1 (de)	2017-10-16	2020-08-26	Voyager Therapeutics, Inc.	Behandlung von amyotropher lateralsklerose (als)
TW202413649A (zh)	2017-10-16	2024-04-01	美商航海家醫療公司	肌萎縮性脊髓側索硬化症(als)之治療
EP3703723A4 (de)	2017-10-31	2021-12-15	KaliVir Immunotherapeutics, Inc.	Onkolytischer plattformvektor zur systemischen abgabe
KR20250136930A (ko)	2018-03-06	2025-09-16	프레시전 인코포레이티드	사람 파필로마바이러스 백신 및 이의 용도
IL277128B2 (en)	2018-03-06	2025-11-01	Precigen Inc	Hepatitis b vaccines and uses of the same
JP7429192B2 (ja)	2018-04-06	2024-02-07	デイナファーバーキャンサーインスティチュート，インコーポレイテッド	Ｈｈｌａ２受容体としてのｋｉｒ３ｄｌ３、抗ｈｈｌａ２抗体、およびその使用
MX2020011386A (es)	2018-04-27	2021-01-29	Spacecraft Seven Llc	Terapia genica para la degeneracion del snc.
DK3807316T3 (da)	2018-06-18	2024-07-29	Innate Pharma	Sammensætninger og fremgangsmåder til behandling af cancer
WO2020010035A1 (en)	2018-07-02	2020-01-09	Voyager Therapeutics, Inc.	Cannula system
US20210254103A1 (en)	2018-07-02	2021-08-19	Voyager Therapeutics, Inc.	Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
KR102918544B1 (ko)	2018-07-12	2026-01-27	로켓 파마슈티컬스, 리미티드	다논병을 치료하기 위한 유전자 요법 벡터
EP3870703A1 (de)	2018-10-22	2021-09-01	The United States of America, as represented by the Secretary, Department of Health and Human Services	Rekombinantes gp120-protein mit v1-schleifendeletion
US20220054597A1 (en)	2018-10-29	2022-02-24	INSERM (Institut National de la Santé et de la Recherche Médicale)	Expression vector for cholesterol 24-hydrolase in therapy of amyotrophic lateral sclerosis
WO2020148207A1 (en)	2019-01-14	2020-07-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	Human monoclonal antibodies binding to hla-a2
WO2020148338A1 (en)	2019-01-15	2020-07-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy
JP7652705B2 (ja)	2019-03-20	2025-03-27	イムチェックセラピューティクスエスエーエス	Ｂｔｎ２に対する特異性を有する抗体及びその使用
EP3942026A1 (de)	2019-03-22	2022-01-26	Université de Paris	Neue inhibitoren der lrrk2/pp1-interaktion
JP2022526334A (ja)	2019-03-25	2022-05-24	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	新たなタウ種を標的化することによるタウオパチー障害の処置の方法
EP3972997A1 (de)	2019-05-20	2022-03-30	Institut National de la Santé et de la Recherche Médicale (INSERM)	Neuartige anti-cd25-antikörper
JP7624410B2 (ja)	2019-05-21	2025-01-30	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	レット症候群の治療におけるコレステロール２４－ヒドロラーゼのための発現ベクター
EP3986453A1 (de)	2019-06-20	2022-04-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Konformationale anti-protease-nexin-1-einzeldomänenantikörper und verwendungen davon
EP3997225A1 (de)	2019-07-10	2022-05-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verfahren zur behandlung von epilepsie
EP3999540A1 (de)	2019-07-16	2022-05-25	Institut National de la Santé et de la Recherche Médicale (INSERM)	Antikörper mit spezifizität für cd38 und verwendungen davon
WO2021009299A1 (en)	2019-07-17	2021-01-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Bcl-xl:fkbp12 fusion proteins suitable for screening agents capable of slowing down the aging process
US20210032370A1 (en)	2019-08-02	2021-02-04	Immatics Biotechnologies Gmbh	Recruiting agent further binding an mhc molecule
WO2021023624A1 (en)	2019-08-02	2021-02-11	Orega Biotech	Novel il-17b antibodies
DE102019121007A1 (de)	2019-08-02	2021-02-04	Immatics Biotechnologies Gmbh	Antigenbindende Proteine, die spezifisch an MAGE-A binden
WO2021028837A1 (en)	2019-08-13	2021-02-18	Waters Technologies Corporation	Affinity resins and sample preparation devices based on cartilaginous fish ignar derived binding domains
EP4025206A1 (de)	2019-09-02	2022-07-13	Institut National de la Santé et de la Recherche Médicale (INSERM)	Verfahren und zusammensetzungen zur behandlung von krankheiten im zusammenhang mit pax6-mangel
JP7588139B2 (ja)	2019-09-04	2024-11-21	インサーム（インスティテュナシオナルドゥラサンテエドゥラルシェルシェメディカル）	慢性閉塞性肺疾患の急性増悪の処置のためのｉｌ２０－ｒｂに特異的な抗体及びその使用
WO2021048171A1 (en)	2019-09-10	2021-03-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method to improve phagocytosis
AU2020356334A1 (en)	2019-09-24	2022-03-31	Université Catholique de Louvain	Modified vesicular stomatitis virus glycoprotein and uses thereof for the treatment of brain tumors
EP4034560A1 (de)	2019-09-27	2022-08-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anti-müller-hemmungssubstanz-antikörper und verwendungen davon
WO2021058729A1 (en)	2019-09-27	2021-04-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
WO2021059181A1 (en)	2019-09-27	2021-04-01	Pfizer Inc.	Neisseria meningitidis compositions and methods thereof
KR20220076510A (ko)	2019-10-08	2022-06-08	트러스티스 오브 보스톤 칼리지	다수의 서로 다른 비천연 아미노산을 함유하는 단백질 및 이러한 단백질의 제조 및 사용 방법
EP3812008A1 (de)	2019-10-23	2021-04-28	Gamamabs Pharma	Amh-kompetitiver antagonistischer antikörper
CN110656090B (zh) *	2019-10-28	2023-06-30	嘉兴安宇生物科技有限公司	一种表达质粒、用于包装容量增加的二代腺病毒的细胞株及其应用
CN110714027A (zh) *	2019-10-28	2020-01-21	嘉铭(固安)生物科技有限公司	一种表达质粒、用于包装二代腺病毒的细胞株及其应用
US20230016983A1 (en)	2019-11-19	2023-01-19	lNSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)	Antisense oligonucleotides and thier use for the treatment of cancer
JP2023502712A (ja)	2019-11-21	2023-01-25	インサーム（インスティテュナシオナルドゥラサンテエドゥラルシェルシェメディカル）	抗ｐｄ－１／ｉｌ－１５免疫サイトカインによる新しいｐｄ－１標的免疫療法
EP4065600A1 (de)	2019-11-25	2022-10-05	Cornell University	Apoe-gentherapie
EP4072682A1 (de)	2019-12-09	2022-10-19	Institut National de la Santé et de la Recherche Médicale (INSERM)	Antikörper mit spezifität gegen her4 und verwendungen davon
EP4090365A1 (de)	2020-01-15	2022-11-23	Immatics Biotechnologies GmbH	Antigenbindende proteine, die spezifisch prame binden
AU2021213735A1 (en)	2020-01-30	2022-09-22	Umoja Biopharma, Inc.	Bispecific transduction enhancer
WO2021163365A1 (en)	2020-02-11	2021-08-19	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Sars-cov-2 vaccine
WO2021175954A1 (en)	2020-03-04	2021-09-10	Imcheck Therapeutics Sas	Antibodies having specificity for btnl8 and uses thereof
CN115484978A (zh)	2020-03-05	2022-12-16	尼奥克斯医疗有限公司	使用免疫细胞治疗癌症的方法和组合物
US11213482B1 (en)	2020-03-05	2022-01-04	University of Pittsburgh—Of the Commonwealth System of Higher Educat	SARS-CoV-2 subunit vaccine and microneedle array delivery system
US11773391B2 (en)	2020-04-01	2023-10-03	University of Pittsburgh—of the Commonwealth System of Higher Education	Therapeutic and diagnostic target for SARS-CoV-2 and COVID-19
WO2021222639A2 (en)	2020-04-29	2021-11-04	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Recombinant human metapneumovirus f proteins and their use
CA3180683A1 (en)	2020-05-12	2021-11-18	Inserm (Institut National De La Sante Et De La Recherche Medicale)	New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
WO2021247995A2 (en)	2020-06-04	2021-12-09	Voyager Therapeutics, Inc.	Compositions and methods of treating neuropathic pain
KR20230030644A (ko)	2020-06-29	2023-03-06	인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)	항-단백질 단일-도메인 항체 및 이를 포함하는 폴리펩타이드
KR20230043869A (ko)	2020-08-07	2023-03-31	스페이스크래프트 세븐, 엘엘씨	Aav 벡터를 사용한 플라코필린-2(pkp2) 유전자 요법
WO2022035860A2 (en)	2020-08-10	2022-02-17	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Replication-competent adenovirus type 4-hiv env vaccines and their use
AU2021335257A1 (en)	2020-09-04	2023-03-09	Merck Patent Gmbh	Anti-CEACAM5 antibodies and conjugates and uses thereof
AU2021379882A1 (en)	2020-11-10	2023-06-29	Sanofi	Ceacam5 antibody-drug conjugate formulation
MX2023005570A (es)	2020-11-12	2023-05-29	Inst Nat Sante Rech Med	Anticuerpos conjugados o fusionados al dominio de union del receptor de la proteina de la espicula de sars-cov-2 y usos de los mismos con fines de vacunacion.
TW202227621A (zh)	2020-11-19	2022-07-16	美商凱立凡爾免疫治療股份有限公司	重塑腫瘤微環境的溶瘤免疫療法
EP4267176A1 (de)	2020-12-23	2023-11-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Chlamydia-impfstoff auf basis des momp-vs4-antigen-targeting auf antigenpräsentierenden zellen
WO2022152698A1 (en)	2021-01-12	2022-07-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of npdk-d to evaluate cancer prognosis
US20250282870A1 (en)	2021-01-20	2025-09-11	Bioentre Llc	Ctla4-binding proteins and methods of treating cancer
AU2022212952A1 (en)	2021-01-27	2023-08-10	Umoja Biopharma, Inc.	Lentivirus for generating cells expressing anti-cd19 chimeric antigen receptor
US20240124532A1 (en)	2021-01-29	2024-04-18	Institut National De La Santé Et De La Recherche Médicale (Inserm)	Chlamydia trachomatis antigenic polypeptides and uses thereof for vaccine purposes
WO2022184805A1 (en)	2021-03-03	2022-09-09	Immatics Biotechnologies Gmbh	Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein
WO2022200469A1 (en)	2021-03-24	2022-09-29	INSERM (Institut National de la Santé et de la Recherche Médicale)	A dominant negative protein of rad51 for treating cancer
EP4322938A1 (de)	2021-04-14	2024-02-21	Institut National de la Santé et de la Recherche Médicale (INSERM)	Neues verfahren zur verbesserung der zytotoxizität von nk-zellen
EP4322937A1 (de)	2021-04-14	2024-02-21	Institut National de la Santé et de la Recherche Médicale (INSERM)	Neues verfahren zur verbesserung der antitumoraktivität von makrophagen
WO2022232648A1 (en)	2021-04-29	2022-11-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Prefusion-stabilized lassa virus glycoprotein complex and its use
BR112023022681A2 (pt)	2021-04-30	2024-01-23	Kalivir Immunotherapeutics Inc	Vírus oncolíticos para expressão modificada de mhc
WO2022233956A1 (en)	2021-05-05	2022-11-10	Immatics Biotechnologies Gmbh	Antigen binding proteins specifically binding prame
EP4337245A1 (de)	2021-05-13	2024-03-20	Universidade Do Algarve	Isolierte oder künstliche nukleotidsequenzen zur verwendung bei neurodegenerativen erkrankungen
PE20240779A1 (es)	2021-07-27	2024-04-17	Immatics Biotechnologies Gmbh	Proteinas de union a antigenos que se unen especificamente a ct45
WO2023012165A1 (en)	2021-08-02	2023-02-09	Universite De Montpellier	Compositions and methods for treating cmt1a or cmt1e diseases with rnai molecules targeting pmp22
EP4130038A1 (de)	2021-08-03	2023-02-08	Institut national de recherche pour l'agriculture, l'alimentation et l'environnement	Anti-il-2-antikörper, komplex damit und verwendungen davon
WO2023015186A1 (en)	2021-08-03	2023-02-09	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
US20240366681A1 (en)	2021-08-13	2024-11-07	Triovance Holding Llc	A skin substitute composition and methods of producing and using the same
CA3234809A1 (en)	2021-10-20	2023-04-27	Steven Goldman	Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss
EP4426331A1 (de)	2021-11-02	2024-09-11	University of Rochester	Tcf7l2-vermittelte remyelinisierung im gehirn
EP4433584A1 (de)	2021-11-15	2024-09-25	Technische Universität Dresden	Ortsspezifische rekombinasen zur effizienten und spezifischen genomeditierung
WO2023088968A1 (en)	2021-11-17	2023-05-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Universal sarbecovirus vaccines
WO2023091696A1 (en)	2021-11-19	2023-05-25	Christiana Care Gene Editing Institute, Inc.	Adenovirus delivery system for cancer treatment
US20250002596A1 (en)	2021-12-01	2025-01-02	Institut National de la Santé et de la Recherche Médicale	Neutralizing anti-cd95l monoclonal antibodies
EP4209508A1 (de)	2022-01-11	2023-07-12	Centre national de la recherche scientifique	Nanokörpern für das deneddylierende enzym nedp1
JP2025504081A (ja)	2022-02-01	2025-02-06	コーネル・ユニバーシティー	フリードライヒ運動失調症に関連する心筋症の治療及び予防のための方法及び医薬組成物
WO2023156437A1 (en)	2022-02-16	2023-08-24	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anti-robo4 human monoclonal antibodies and uses thereof for the treatment of cancer
CN118871466A (zh)	2022-02-25	2024-10-29	Inserm(法国国家健康医学研究院)	阻止金属蛋白酶裂解cd95l的抗体
US20250179210A1 (en)	2022-03-09	2025-06-05	Merck Patent Gmbh	Anti-ceacam5 antibodies and conjugates and uses thereof
EP4490172A1 (de)	2022-03-11	2025-01-15	Institut National De La Sante Et De La Recherche Medicale - Inserm	Nukleinsäuresystem zur spezifischen neuprogrammierung von b- und t-zellen und verwendungen davon
US20250197455A1 (en)	2022-03-27	2025-06-19	TThe United States of America, as represented by the Secretary, Department of Health and Human Servi	Base-covered hiv-1 envelope ectodomains and their use
WO2023196898A1 (en)	2022-04-07	2023-10-12	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Beta globin mimetic peptides and their use
US20250223326A1 (en)	2022-05-10	2025-07-10	Institut National de la Santé et de la Recherche Médicale	Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells
WO2023240287A1 (en)	2022-06-10	2023-12-14	Bioentre Llc	Combinations of ctla4 binding proteins and methods of treating cancer
EP4551711A1 (de)	2022-07-08	2025-05-14	Cornell University	Verfahren und pharmazeutische zusammensetzungen zur behandlung und prävention von morbus alzheimer
WO2024017990A1 (en)	2022-07-21	2024-01-25	Institut National de la Santé et de la Recherche Médicale	Methods and compositions for treating chronic pain disorders
WO2024052503A1 (en)	2022-09-08	2024-03-14	Institut National de la Santé et de la Recherche Médicale	Antibodies having specificity to ltbp2 and uses thereof
EP4587473A1 (de)	2022-09-12	2025-07-23	Institut National de la Santé et de la Recherche Médicale	Neue anti-itgb8-antikörper und ihre verwendungen
WO2024061930A1 (en)	2022-09-22	2024-03-28	Institut National de la Santé et de la Recherche Médicale	New method to treat and diagnose peripheral t-cell lymphoma (ptcl)
WO2024074571A1 (en)	2022-10-05	2024-04-11	Institut National de la Santé et de la Recherche Médicale	Dc-targeting vaccine against nipah virus infection
EP4601743A1 (de)	2022-10-14	2025-08-20	Institut National de la Santé et de la Recherche Médicale	Verfahren und pharmazeutische zusammensetzung zur behandlung von alpha-synukleinopathien
PT118269A (pt)	2022-10-20	2024-04-22	Univ Aveiro	Pkmyt1 for use in regenerative medicine
WO2024091824A1 (en)	2022-10-26	2024-05-02	Ada Forsyth Institute, Inc.	Differentiation and reprogramming of chondrocyte
TW202434735A (zh)	2022-11-04	2024-09-01	美商烏莫賈生物製藥股份有限公司	展示黏著分子融合的顆粒
KR20250121163A (ko)	2022-11-04	2025-08-11	우모자 바이오파마 인코포레이티드	융합 분자를 디스플레이하는 렌티바이러스 입자 및 이의 용도
EP4646478A1 (de)	2023-01-06	2025-11-12	Institut National de la Santé et de la Recherche Médicale	Intravenöse verabreichung von antisense-oligonukleotiden zur behandlung von schmerzen
EP4658303A1 (de)	2023-02-02	2025-12-10	Institut National de la Santé et de la Recherche Médicale	Anti-tuberkulose-impfstoff gegen ausgewählte schützende mycobacterium-tuberkulose-antigene auf dendritische zellen
EP4658294A2 (de)	2023-02-02	2025-12-10	University of Rochester	Kompetitiver ersatz von gliazellen
WO2024170543A1 (en)	2023-02-14	2024-08-22	Institut National de la Santé et de la Recherche Médicale	Anti-cd44 antibodies and uses thereof
EP4669330A1 (de)	2023-02-21	2025-12-31	Institut National de la Santé et de la Recherche Médicale	Verfahren und pharmazeutische zusammensetzung zur behandlung des sanfilippo-syndroms vom typ iiib
EP4688843A1 (de)	2023-03-30	2026-02-11	272Bio Limited	Gnrh-bindende polypeptide und verwendungen davon
WO2024220719A1 (en)	2023-04-18	2024-10-24	Crystal Ronald G	Modified aav capsids for gene delivery
WO2024220722A1 (en)	2023-04-18	2024-10-24	Cornell University	Compositions and methods for tissue- specific expression of gene therapies
CN121335984A (zh)	2023-04-18	2026-01-13	康奈尔大学	用于治疗和预防阿尔茨海默病的方法和apoe药物组合物
EP4713467A1 (de)	2023-05-15	2026-03-25	Umoja Biopharma, Inc.	Lentivirale verabreichung von chimären anti-cd20-antigenrezeptoren
EP4713371A1 (de)	2023-05-17	2026-03-25	Institut National de la Santé et de la Recherche Médicale	Anti-cathepsin-d-antikörper
WO2024249626A1 (en)	2023-05-30	2024-12-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Hiv-1 envelope triple tandem trimers and their use
EP4724809A2 (de)	2023-06-08	2026-04-15	Cornell University	Satseq: modulares system zur kopplung von sättigungsmutagenese, dna-barcodierung und tiefer sequenzierung
EP4731681A1 (de)	2023-06-23	2026-04-29	Imcheck Therapeutics	Bispezifische antikörper gegen btn3a und die pd-1/pd-l1-hemmende achse
WO2025008406A1 (en)	2023-07-04	2025-01-09	Institut National de la Santé et de la Recherche Médicale	Antisense oligonucleotides and their use for the treatment of cancer
WO2025012417A1 (en)	2023-07-13	2025-01-16	Institut National de la Santé et de la Recherche Médicale	Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
WO2025021839A1 (en)	2023-07-25	2025-01-30	Institut National de la Santé et de la Recherche Médicale	Method to treat metabolic disorders
CN121358777A (zh)	2023-07-27	2026-01-16	伊玛提克斯生物技术有限公司	抗mageb2的抗原结合蛋白
WO2025021979A1 (en)	2023-07-27	2025-01-30	Immatics Biotechnologies Gmbh	Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same
WO2025032158A1 (en)	2023-08-08	2025-02-13	Institut National de la Santé et de la Recherche Médicale	Method to treat tauopathies
WO2025045915A1 (en)	2023-08-29	2025-03-06	Institut National de la Santé et de la Recherche Médicale	Methods for inducing muscle hypertrophy
WO2025073890A1 (en)	2023-10-06	2025-04-10	Institut National de la Santé et de la Recherche Médicale	Method to capture circulating tumor extracellular vesicles
WO2025090427A1 (en)	2023-10-23	2025-05-01	University Of Rochester	Glial-targeted relief of hyperexcitability in neurodegenerative diseases
US12410436B2 (en) *	2023-10-31	2025-09-09	Lonza Houston, Inc.	Adeno-associated virus (AAV) producer cell lines
EP4563586A1 (de)	2023-11-28	2025-06-04	Université Paris Cité	Neue inhibitoren der lrrk2/pp1-interaktion
WO2025120015A1 (en)	2023-12-06	2025-06-12	Institut National de la Santé et de la Recherche Médicale	Cd5 targeting antibodies with depleting and t or b-cell activation effects
WO2025157848A1 (en)	2024-01-23	2025-07-31	Institut National de la Santé et de la Recherche Médicale	Methods for the intravenous treatment of sanfilippo syndrome type iiib
WO2025171001A1 (en)	2024-02-06	2025-08-14	Regeneron Pharmaceuticals, Inc.	Compositions and methods for improved production of aav viral vectors
WO2025186293A1 (en)	2024-03-06	2025-09-12	Institut National de la Santé et de la Recherche Médicale	Chmp2b mutants for use for treating infection
WO2025202674A1 (en)	2024-03-27	2025-10-02	Institut National de la Santé et de la Recherche Médicale	Langerhans cells targeting hiv-1 vaccines
WO2025215206A1 (en)	2024-04-12	2025-10-16	Institut National de la Santé et de la Recherche Médicale	Activator of primary cilia to treat cognitive dysfunctions or ciliopathies
WO2025224297A1 (en)	2024-04-26	2025-10-30	Institut National de la Santé et de la Recherche Médicale	Antibodies having specificity to tgfbi and uses thereof
WO2025233431A1 (en)	2024-05-07	2025-11-13	Immatics Biotechnologies Gmbh	Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof
WO2025233432A1 (en)	2024-05-07	2025-11-13	Immatics Biotechnologies Gmbh	Use and dosage of an antigen-binding protein comprising a tcr specific for an hla-a*02 restricted peptide
WO2025235604A1 (en)	2024-05-08	2025-11-13	Umoja Biopharma, Inc.	Fusion protein for use as immune cell engager
WO2025237990A1 (en)	2024-05-14	2025-11-20	Institut National de la Santé et de la Recherche Médicale	Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
WO2025242732A1 (en)	2024-05-21	2025-11-27	Institut National de la Santé et de la Recherche Médicale	Pan antibodies against sars-cov-2 spike protein and uses thereof for therapeutical purposes
WO2025247913A1 (en)	2024-05-28	2025-12-04	Institut National de la Santé et de la Recherche Médicale	Anti-ifn-omega1 monoclonal antibodies
WO2025247918A1 (en)	2024-05-28	2025-12-04	Institut National de la Santé et de la Recherche Médicale	ANTI-IFN-α2 MONOCLONAL ANTIBODIES
WO2025247917A1 (en)	2024-05-28	2025-12-04	Institut National de la Santé et de la Recherche Médicale	ANTI-IFN-α2 AND ANTI-IFN-ω1 MONOCLONAL ANTIBODIES
WO2025247924A1 (en)	2024-05-28	2025-12-04	Institut National de la Santé et de la Recherche Médicale	ANTI-IFN-α2 MONOCLONAL ANTIBODIES
WO2025248097A2 (en)	2024-05-31	2025-12-04	Gamamabs Pharma	Humanized anti-human her3 antibodies and uses thereof
WO2025252857A1 (en)	2024-06-05	2025-12-11	Institut National de la Santé et de la Recherche Médicale	Il-15 muteins with ph-dependent binding for il-15ralpha
WO2025252855A1 (en)	2024-06-05	2025-12-11	Institut National de la Santé et de la Recherche Médicale	IL-15 MUTEINS WITH PH-DEPENDENT BINDING FOR IL-15Rbeta
WO2025257181A1 (en)	2024-06-11	2025-12-18	Institut National de la Santé et de la Recherche Médicale	Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)
WO2025262304A1 (en)	2024-06-20	2025-12-26	Sanofi	Binding proteins comprising an anti-immune checkpoint antibody or a fragment thereof and single-chain tnfrsf ligand multimers
WO2026003242A1 (en)	2024-06-28	2026-01-02	Institut National de la Santé et de la Recherche Médicale	Dendritic cells-targeting vaccine against hbv infection
WO2026030724A1 (en)	2024-08-01	2026-02-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Sars-cov-2 vaccine
WO2026033259A1 (en)	2024-08-05	2026-02-12	Lys Therapeutics	Antibodies for treating neurological and neurovascular disorders
WO2026033136A1 (en)	2024-08-09	2026-02-12	Immatics Biotechnologies Gmbh	Advanced treatment modalities for anti-prame tcr-engineered immune cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1024198A3 (de) *	1992-12-03	2002-05-29	Genzyme Corporation	Pseudo-adenovirenvectors zur Gentherapie der Hämophilien
FR2705686B1 (fr) *	1993-05-28	1995-08-18	Transgene Sa	Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
SK282843B6 (sk) *	1993-07-13	2002-12-03	Rhone-Poulenc Rorer S. A.	Defektný rekombinantný adenovírus a farmaceutický prostriedok s jeho obsahom
FR2707664B1 (fr) *	1993-07-13	1995-09-29	Centre Nat Rech Scient	Vecteurs viraux et utilisation en thérapie génique.
US6686200B1 (en) *	1993-08-31	2004-02-03	Uab Research Foundation	Methods and compositions for the large scale production of recombinant adeno-associated virus
FR2716682B1 (fr) *	1994-01-28	1996-04-26	Centre Nat Rech Scient	Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations.
FR2716893B1 (fr) *	1994-03-03	1996-04-12	Rhone Poulenc Rorer Sa	Virus recombinants, leur préparation et leur utilisation thérapeutique.
FR2726285B1 (fr) *	1994-10-28	1996-11-29	Centre Nat Rech Scient	Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
US5872005A (en) *	1994-11-03	1999-02-16	Cell Genesys Inc.	Packaging cell lines for adeno-associated viral vectors
WO1996018418A1 (en) *	1994-12-12	1996-06-20	Genetic Therapy, Inc.	Improved adenoviral vectors and producer cells

1996
- 1996-01-18 IL IL11681696A patent/IL116816A/xx not_active IP Right Cessation
- 1996-01-19 SK SK990-97A patent/SK99097A3/sk unknown
- 1996-01-19 CA CA002210168A patent/CA2210168A1/fr not_active Abandoned
- 1996-01-19 HU HU9702404A patent/HU222191B1/hu not_active IP Right Cessation
- 1996-01-19 AU AU45443/96A patent/AU717253B2/en not_active Ceased
- 1996-01-19 BR BR9606971A patent/BR9606971A/pt not_active IP Right Cessation
- 1996-01-19 MX MX9704552A patent/MX9704552A/es not_active IP Right Cessation
- 1996-01-19 CZ CZ19972306A patent/CZ294969B6/cs not_active IP Right Cessation
- 1996-01-19 KR KR1019970704903A patent/KR100510822B1/ko not_active Expired - Fee Related
- 1996-01-19 US US08/875,223 patent/US6127175A/en not_active Expired - Fee Related
- 1996-01-19 JP JP8522091A patent/JPH11504502A/ja active Pending
- 1996-01-19 WO PCT/FR1996/000088 patent/WO1996022378A1/fr not_active Ceased
- 1996-01-19 EP EP96901417A patent/EP0805868A1/de not_active Withdrawn
- 1996-01-19 FI FI973055A patent/FI973055L/fi not_active IP Right Cessation
1997
- 1997-07-18 NO NO19973332A patent/NO320382B1/no unknown

Also Published As

Publication number	Publication date
MX9704552A (es)	1997-10-31
EP0805868A1 (de)	1997-11-12
CZ294969B6 (cs)	2005-04-13
HUP9702404A3 (en)	1999-10-28
HUP9702404A2 (hu)	1998-04-28
FI973055A0 (fi)	1997-07-18
CA2210168A1 (fr)	1996-07-25
IL116816A (en)	2003-05-29
IL116816A0 (en)	1996-05-14
HU222191B1 (hu)	2003-05-28
WO1996022378A1 (fr)	1996-07-25
KR19980701512A (ko)	1998-05-15
BR9606971A (pt)	1997-11-04
KR100510822B1 (ko)	2005-12-19
CZ230697A3 (en)	1997-10-15
FI973055A7 (fi)	1997-07-18
NO973332L (no)	1997-07-18
US6127175A (en)	2000-10-03
FI973055L (fi)	1997-07-18
NO320382B1 (no)	2005-11-28
NO973332D0 (no)	1997-07-18
JPH11504502A (ja)	1999-04-27
AU717253B2 (en)	2000-03-23
AU4544396A (en)	1996-08-07

Publication	Publication Date	Title
SK99097A3 (en)	1998-02-04	Cells for the production of recombinant adenoviruses
JP3821846B2 (ja)	2006-09-13	組換えアデノウイルス、ａａｖを作製するためのその使用、相補的細胞系、及び、該アデノウイルスを含む医薬組成物
KR100403708B1 (ko)	2004-05-31	재조합아데노-수반바이러스(aav)제조방법및이의용도
RU2219241C2 (ru)	2003-12-20	Дефектный рекомбинантный аденовирусный вектор (варианты)
US6468771B1 (en)	2002-10-22	Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal DNA of target cells
US5856152A (en)	1999-01-05	Hybrid adenovirus-AAV vector and methods of use therefor
US6387368B1 (en)	2002-05-14	Hybrid adenovirus-AAV virus and methods of use thereof
HUP0003331A2 (hu)	2001-02-28	Eljárás a C-szerocsoportba nem besorolható adenovirális vektorok előállítására
WO2001023597A9 (en)	2001-11-22	Cell lines and constructs useful in production of e1-deleted adenoviruses in absence of replication competent adenovirus
JPH10508491A (ja)	1998-08-25	新規なアデノウイルスベクター、パッケージング細胞系、組換えアデノウイルスおよび方法
JP3827163B2 (ja)	2006-09-27	遺伝子治療用のアデノウイルスベクター
KR100484441B1 (ko)	2006-01-27	IVa2유전자가불활성화된결손재조합아데노바이러스
AU3926599A (en)	1999-11-01	Preparation of recombinant adenovirus carrying a rep gene of adeno-associated virus
FR2738575A1 (fr)	1997-03-14	Cellules pour la production d'adenovirus recombinants
FR2741891A1 (fr)	1997-06-06	Cellules pour la production d'adenovirus recombinants